<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL document created with XMark (C) by Bowne Inc. --> <!-- Based on XBRL 2.1 -->
<!--Merged instance document: C:\Documents and Settings\Saurabh\Desktop\Biogen\biib-20090630.xml-->
<!--merged on: 7/17/2009 2:20:18 AM--> <xbrl
xmlns="http://www.xbrl.org/2003/instance"
xmlns:link="http://www.xbrl.org/2003/linkbase"
xmlns:xlink="http://www.w3.org/1999/xlink"
xmlns:biib="http://biogenidec.com/20090630"
xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
xmlns:us-gaap="http://xbrl.us/us-gaap/2008-03-31"
xmlns:xbrli="http://www.xbrl.org/2003/instance"
xmlns:dei="http://xbrl.us/dei/2008-03-31"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"> <link:schemaRef
xlink:type="simple" xlink:href="biib-20090630.xsd" /> <!-- Context Section -->
<context id="BalanceAsOf_30Jun2008"> <entity> <identifier
scheme="http://www.sec.gov/CIK">0000875045</identifier> </entity> <period>
<instant>2008-06-30</instant> </period> </context> <context
id="BalanceAsOf_31Dec2007"> <entity> <identifier
scheme="http://www.sec.gov/CIK">0000875045</identifier> </entity> <period>
<instant>2007-12-31</instant> </period> </context> <context
id="BalanceAsOf_13Jul2009"> <entity> <identifier
scheme="http://www.sec.gov/CIK">0000875045</identifier> </entity> <period>
<instant>2009-07-13</instant> </period> </context> <context
id="BalanceAsOf_30Jun2009"> <entity> <identifier
scheme="http://www.sec.gov/CIK">0000875045</identifier> </entity> <period>
<instant>2009-06-30</instant> </period> </context> <context
id="BalanceAsOf_31Dec2008"> <entity> <identifier
scheme="http://www.sec.gov/CIK">0000875045</identifier> </entity> <period>
<instant>2008-12-31</instant> </period> </context> <context
id="ThreeMonthsEnded_30Jun2009"> <entity> <identifier
scheme="http://www.sec.gov/CIK">0000875045</identifier> </entity> <period>
<startDate>2009-04-01</startDate> <endDate>2009-06-30</endDate> </period>
</context> <context id="ThreeMonthsEnded_30Jun2008"> <entity> <identifier
scheme="http://www.sec.gov/CIK">0000875045</identifier> </entity> <period>
<startDate>2008-04-01</startDate> <endDate>2008-06-30</endDate> </period>
</context> <context id="SixMonthsEnded_30Jun2008"> <entity> <identifier
scheme="http://www.sec.gov/CIK">0000875045</identifier> </entity> <period>
<startDate>2008-01-01</startDate> <endDate>2008-06-30</endDate> </period>
</context> <context id="January-01-2009_June-30-2009"> <entity> <identifier
scheme="http://www.sec.gov/CIK">0000875045</identifier> </entity> <period>
<startDate>2009-01-01</startDate> <endDate>2009-06-30</endDate> </period>
</context> <!--Unit Section--> <unit id="USDEPS"> <divide> <unitNumerator>
<measure>iso4217:USD</measure> </unitNumerator> <unitDenominator> <measure>xbrli:shares</measure>
</unitDenominator> </divide> </unit> <unit id="Shares"> <measure>xbrli:shares</measure>
</unit> <unit id="USD"> <measure>iso4217:USD</measure> </unit> <!-- Element Section -->
<!-- Begin Block Tagged Note --> <biib:EquityNoteDisclosureTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 8 - us-gaap:EarningsPerSharePolicyTextBlock--&gt; &lt;div style="margin-left:
0%"&gt; &lt;table width="100%" border="0" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;tr&gt; &lt;td width="3%"&gt;&lt;/td&gt; &lt;td width="97%"&gt;&lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;8.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Equity&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; The following tables reflects the reconciliation
at the beginning and the end of the period of the carrying amount of equity
attributable to the shareholders of Biogen Idec Inc., equity attributable
to noncontrolling interests, and total equity (in millions): &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;table border="0" width="100%" align="center" cellpadding="0" cellspacing="0"
style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt; &lt;tr style="font-size:
1pt" valign="bottom"&gt; &lt;td width="40%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="7%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=lead --&gt; &lt;td width="7%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="10" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;For the&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Three Months Ended June&amp;#160;30, 2009&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Three Months Ended June&amp;#160;30, 2008&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Biogen
Idec Inc.&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Biogen Idec Inc.&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Shareholders&amp;#8217;&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Noncontrolling&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Shareholders&amp;#8217;&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Noncontrolling&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Equity&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Interest&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;Total Equity&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;Equity&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Interest&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Total Equity&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height: 3pt; font-size:
1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Beginning Balance
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &lt;b&gt;5,987.7&lt;/b&gt; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&lt;b&gt;32.6&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &lt;b&gt;6,020.3&lt;/b&gt; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&lt;b&gt;5,532.7&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &lt;b&gt;24.7&lt;/b&gt;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &lt;b&gt;5,557.4&lt;/b&gt; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left: 9pt"&gt;
Comprehensive income: &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-9pt; margin-left: 18pt"&gt; Net income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
142.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 2.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 144.9 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
206.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 1.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 208.0 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 18pt"&gt; Unrealized gains(losses)
on securities available for sale, net of tax of $(0.8) and $3.5 &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1.4 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(6.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (6.1 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left: 18pt"&gt;
Unrealized gains(losses) on foreign currency forward contracts, net of tax
of $2.6 and $(3.8) &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (16.3 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (16.3 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 6.5 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 6.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -9pt;
margin-left: 18pt"&gt; Unrealized gains(losses) on pension benefit obligation,
net of tax of $0 &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 0.1 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 0.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left: 18pt"&gt;
Translation adjustments &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 58.4 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(1.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 57.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (2.7 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (0.1 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(2.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left: 18pt"&gt;
Comprehensive income (loss) &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 186.5
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 0.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 187.1 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 204.3
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 205.6 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Distribution to noncontrolling
interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (1.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (1.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Capital contribution
from noncontrolling interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 1.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1.6 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left: 9pt"&gt;
Repurchase of common stock for Treasury, at cost &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (319.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(319.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Issuance of common
stock from conversion of subordinated notes payable &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 0.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 0.1 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
align="left" valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left:
9pt"&gt; Issuance of common stock under stock option and stock purchase plans
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 7.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
7.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 61.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 61.2
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Issuance of common
stock under stock award plans &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (2.0
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (2.0 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (1.8 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (1.8 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div
style="text-indent: -9pt; margin-left: 9pt"&gt; Compensation expense related
to share-based payments &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 42.5 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 42.5 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 35.0
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 35.0 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Tax benefit from share-based
payments &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; (9.5 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (9.5 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 10.9 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 10.9 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-9pt; margin-left: 9pt"&gt; Ending Balance &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&lt;b&gt;6,212.5&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &lt;b&gt;&amp;#160;&amp;#160;33.2&lt;/b&gt;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &lt;b&gt;6,245.7&lt;/b&gt; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&lt;b&gt;5,522.9&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &lt;b&gt;&amp;#160;&amp;#160;26.2&lt;/b&gt;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &lt;b&gt;5,549.1&lt;/b&gt; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left: 0%; margin-right:
0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div style="margin-top:
0pt; font-size: 1pt"&gt; &lt;/div&gt; &lt;/div&gt; &lt;!-- END PAGE WIDTH
--&gt; &lt;!-- PAGEBREAK --&gt; &lt;div style="margin-left: 0%"&gt; &lt;!--
BEGIN PAGE WIDTH --&gt; &lt;div style="margin-top: 0pt; font-size: 1pt"&gt;
&lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div align="center" style="margin-left:
0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/i&gt; &lt;/b&gt; &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;table border="0" width="100%" align="center" cellpadding="0" cellspacing="0"
style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt; &lt;tr style="font-size:
1pt" valign="bottom"&gt; &lt;td width="40%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="7%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=lead --&gt; &lt;td width="7%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="10" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;For the&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Six Months Ended June&amp;#160;30, 2009&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Six Months Ended June&amp;#160;30, 2008&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Biogen
Idec Inc.&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Biogen Idec Inc.&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Shareholders&amp;#8217;&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Noncontrolling&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Shareholders&amp;#8217;&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Noncontrolling&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Equity&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Interest&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;Total Equity&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;Equity&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Interest&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Total Equity&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height: 3pt; font-size:
1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Beginning Balance
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &lt;b&gt;5,806.1&lt;/b&gt; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&lt;b&gt;27.9&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &lt;b&gt;5,834.0&lt;/b&gt; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&lt;b&gt;5,534.3&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &lt;b&gt;19.7&lt;/b&gt;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &lt;b&gt;5,554.0&lt;/b&gt; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left: 9pt"&gt;
Comprehensive income: &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-9pt; margin-left: 18pt"&gt; Net income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
386.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 4.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 391.4 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
369.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 4.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 373.9 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 18pt"&gt; Unrealized gains(losses)
on securities available for sale, net of tax of $(2.0) and $3.3 &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 3.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 3.5 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(7.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (7.6 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left: 18pt"&gt;
Unrealized gains(losses) on foreign currency forward contracts, net of tax
of $(0.5) and $3.1 &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 11.9 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 11.9 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (5.3
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (5.3 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -9pt;
margin-left: 18pt"&gt; Unrealized gains on pension benefit obligation, net
of tax of $0 &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 0.1 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 0.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 18pt"&gt; Translation adjustment
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 7.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 0.7 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
7.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 54.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 1.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 56.4 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid
#000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 18pt"&gt; Total comprehensive
income &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 409.2 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 5.3 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
414.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 411.6 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 5.9 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
417.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-9pt; margin-left: 9pt"&gt; Distribution to noncontrolling interest &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (1.4
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(1.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Capital contribution
from noncontrolling interest &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 2.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 2.0 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left: 9pt"&gt;
Repurchase of common stock for Treasury, at cost &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(57.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (57.6 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(559.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (559.7 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div
style="text-indent: -9pt; margin-left: 9pt"&gt; Issuance of common stock from
conversion of subordinated notes payable &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 0.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 0.1 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
align="left" valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left:
9pt"&gt; Issuance of common stock under stock option and stock purchase plans
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 24.4 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 24.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 89.5 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 89.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left: 9pt"&gt;
Issuance of common stock under stock award plans &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(38.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (38.4 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(41.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (41.7 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left: 9pt"&gt;
Compensation expense related to share-based payments &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
82.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 82.0 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
71.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 71.3 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Tax benefit from share-based
payments &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; (13.2 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (13.2 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 17.5 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 17.5 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-9pt; margin-left: 9pt"&gt; Ending Balance &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&lt;b&gt;6,212.5&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &lt;b&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;33.2&lt;/b&gt;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &lt;b&gt;6,245.7&lt;/b&gt; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&lt;b&gt;5,522.9&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &lt;b&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;26.2&lt;/b&gt;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;b&gt;$&lt;/b&gt; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &lt;b&gt;5,549.1&lt;/b&gt; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left: 0%; margin-right:
0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; The adoption of
SFAS&amp;#160;160 has resulted in the reclassification of amounts previously
attributable to minority interest, now referred to as noncontrolling interest,
to a separate component of total equity on the accompanying consolidated balance
sheet. Additionally, net income attributable to noncontrolling interest is
shown separately from net income in the consolidated statements of income.
This reclassification had no effect on our previously reported financial position
or results of operations. Refer to Note&amp;#160;1, &lt;i&gt;Business Overview,
&lt;/i&gt;and Note&amp;#160;12, &lt;i&gt;Other Income (Expense), Net, &lt;/i&gt;of
this &lt;font style="white-space: nowrap"&gt;Form&amp;#160;10-Q&lt;/font&gt;
for additional information on the adoption of SFAS&amp;#160;160. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Prior year amounts related to noncontrolling interest
have been reclassified to conform to the current year presentation as required
by SFAS&amp;#160;160. &lt;/div&gt; &lt;/div&gt; &lt;!-- END PAGE WIDTH --&gt;
&lt;!-- PAGEBREAK --&gt; &lt;div style="margin-left: 0%"&gt; &lt;!-- BEGIN
PAGE WIDTH --&gt; &lt;div style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt;
&lt;div align="center" style="margin-left: 0%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt; &lt;/font&gt;
&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; font-size: 1pt"&gt;
&lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div align="center" style="margin-left:
0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/i&gt; &lt;/b&gt; &lt;/div&gt;
&lt;div style="margin-top: 18pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;/div&gt; &lt;/body&gt; &lt;/html&gt; </biib:EquityNoteDisclosureTextBlock>
<!-- End Block Tagged Note --> <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 1 - biib:BusinessOverviewTextBlock--&gt; &lt;div style="margin-left:
0%"&gt;&lt;!-- BEGIN PAGE WIDTH --&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt;&lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt;&lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;
&lt;div align="center" style="margin-left: 0%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt;&lt;i&gt;&lt;font style="font-size: 9pt; font-family: 'Times New
Roman', Times"&gt;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
0pt; font-size: 1pt"&gt;&lt;/div&gt; &lt;table width="100%" border="0" cellpadding="0"
cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;tr&gt; &lt;td width="3%"&gt;&lt;/td&gt;
&lt;td width="97%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt;
&lt;b&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;1.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Business Overview&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;/table&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Overview&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Biogen Idec Inc.
(&amp;#8220;Biogen Idec,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;us&amp;#8221;
or &amp;#8220;the Company&amp;#8221;) is a global biotechnology company that
creates new standards of care in therapeutic areas with high unmet medical
needs. We currently have four marketed products. Our marketed products are
used for the treatment of multiple sclerosis, or MS, non-Hodgkin&amp;#8217;s
lymphoma, or NHL, rheumatoid arthritis, or RA, Crohn&amp;#8217;s disease and
psoriasis, which are summarized in the table below. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%"
align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family:
'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!--
Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="70%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="21%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=maindata
--&gt; &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=03 type=gutter
--&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=03 type=maindata
--&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="border-bottom: 1px solid #000000; width:
1%; padding-bottom: 1px"&gt; &lt;b&gt;Product&lt;/b&gt; &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="border-bottom: 1px solid #000000; width: 1%; padding-bottom:
1px"&gt; &lt;b&gt;Indications&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height: 3pt; font-size:
1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; &lt;b&gt;&lt;i&gt;AVONEX&lt;sup style="font-size:
85%; vertical-align: text-top"&gt;&amp;#174;&lt;/sup&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; Relapsing MS &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; (interferon beta-1a) &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="font-size: 1pt"&gt; &lt;td colspan="5" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td colspan="5" style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
&lt;b&gt;&lt;i&gt;RITUXAN&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;&amp;#174;&lt;/sup&gt;*&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td align="left"
valign="bottom"&gt; Certain B-cell NHL &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
(rituximab) &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; RA &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td colspan="5" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td colspan="5" style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; &lt;b&gt;&lt;i&gt;TYSABRI&lt;sup style="font-size:
85%; vertical-align: text-top"&gt;&amp;#174;&lt;/sup&gt;**&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; Relapsing MS &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; (natalizumab) &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; Crohn&amp;#8217;s
disease &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="font-size: 1pt"&gt; &lt;td colspan="5" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td colspan="5" style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; &lt;b&gt;&lt;i&gt;FUMADERM&lt;sup style="font-size: 85%; vertical-align:
text-top"&gt;&amp;#174;&lt;/sup&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
Severe psoriasis &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; (dimethylfumarate and monoethylfumarate salts)
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td colspan="5" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td colspan="5" style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div style="font-size: 1pt; margin-left: 0%; width: 13%; align:
left; border-bottom: 1pt solid #000000"&gt; &lt;/div&gt;&lt;!-- callerid=999
iwidth=456 length=60 --&gt; &lt;div style="margin-top: 3pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;table width="100%" border="0" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; &lt;tr&gt; &lt;td width="2%"&gt;&lt;/td&gt; &lt;td
width="1%"&gt;&lt;/td&gt; &lt;td width="97%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt;
&lt;td align="right" valign="top"&gt; *&amp;#160;&lt;/td&gt; &lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; Outside the United States, Canada and Japan, MabThera
is the trade name for rituximab. We refer to rituximab, RITUXAN and MabThera
collectively as RITUXAN.&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:
3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt;
&lt;td align="right" valign="top"&gt; ** &lt;/td&gt; &lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; TYSABRI is indicated in the United States for the
treatment of some patients with moderately to severely active Crohn&amp;#8217;s
disease.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:
12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;Basis of Presentation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; In the opinion of management, the accompanying
unaudited consolidated financial statements include all adjustments, consisting
of only normal recurring accruals, necessary for a fair statement of our financial
position, results of operations and cash flows. The information included in
this quarterly report on &lt;font style="white-space: nowrap"&gt;Form&amp;#160;10-Q&lt;/font&gt;
should be read in conjunction with our consolidated financial statements and
the accompanying notes included in our annual report on &lt;font style="white-space:
nowrap"&gt;Form&amp;#160;10-K&lt;/font&gt; for the year ended December&amp;#160;31,
2008. Our accounting policies are described in the &amp;#8220;Notes to Consolidated
Financial Statements&amp;#8221; in our 2008 annual report on &lt;font style="white-space:
nowrap"&gt;Form&amp;#160;10-K&lt;/font&gt; and updated, as necessary, in this
&lt;font style="white-space: nowrap"&gt;Form&amp;#160;10-Q.&lt;/font&gt; The
year-end consolidated balance sheet data presented for comparative purposes
was derived from audited financial statements, but does not include all disclosures
required by accounting principles generally accepted in the United States.
The results of operations for the three and six months ended June&amp;#160;30,
2009 are not necessarily indicative of the operating results for the full
year or for any other subsequent interim period. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Effective January&amp;#160;1,
2009, we implemented Statement of Financial Accounting Standards No.&amp;#160;160,
&lt;i&gt;Noncontrolling Interests in Consolidated Financial Statements, &lt;/i&gt;an
amendment to ARB No.&amp;#160;51, or SFAS&amp;#160;160. This standard changed
the accounting for and reporting of minority interest (now called noncontrolling
interest) in our consolidated financial statements. Upon adoption, certain
prior period amounts have been reclassified to conform to the current period
financial statement presentation. These reclassifications did not have a material
impact on our previously reported financial position or results of operations.
Refer to Note&amp;#160;8, &lt;i&gt;Equity, &lt;/i&gt;and Note&amp;#160;12,
&lt;i&gt;Other Income (Expense), Net, &lt;/i&gt;of this &lt;font style="white-space:
nowrap"&gt;Form&amp;#160;10-Q&lt;/font&gt; for additional information on the
adoption of SFAS&amp;#160;160. &lt;/div&gt; &lt;div style="margin-top: 12pt;
font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;Principles of Consolidation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; The consolidated financial statements reflect
our financial statements, those of our wholly-owned subsidiaries and of our
joint ventures in Italy and Switzerland, Biogen Domp&amp;#233; SRL and Biogen
Domp&amp;#233; Switzerland Gmbh, respectively. In accordance with the Financial
Accounting Standards Board, or FASB, Interpretation No.&amp;#160;46 (Revised
2003), &lt;i&gt;Consolidation of Variable Interest Entities, &lt;/i&gt;or
FIN&amp;#160;46(R), we consolidate variable interest entities in which we
are the primary beneficiary. For such consolidated entities in which we own
less than a 100% interest, we record net income attributable to noncontrolling
interest (minority interest) in our consolidated statement of income equal
to the percentage of ownership of the respective noncontrolling owners. All
material intercompany balances and transactions have been eliminated in consolidation.
&lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Use of Estimates&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
The preparation of consolidated financial statements in accordance with accounting
principles generally accepted in the United States requires our management
to make estimates and judgments that may affect the reported amounts of assets,
liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. On an on-going basis, we evaluate our estimates, including
those related to revenue recognition and related allowances, marketable securities,
derivatives and hedging activities, inventory, impairments of long-lived assets,
including intangible assets, impairments of goodwill, income taxes including
the valuation allowance for deferred tax assets, valuation of long-lived assets
and investments, research and development, contingencies and litigation, and
share-based payments. We base our estimates on historical experience and on
various other assumptions that are believed to be reasonable, the results
of which form the basis for making judgments about the carrying values of
assets and liabilities. Actual results may differ from these estimates under
different assumptions or conditions. &lt;/div&gt; &lt;div style="margin-top:
12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;Subsequent Events&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Effective this quarter, we implemented Statement
of Financial Accounting Standards No.&amp;#160;165, &lt;i&gt;Subsequent Events,
&lt;/i&gt;or SFAS&amp;#160;165. This standard establishes general standards
of accounting for and disclosure of events that occur after the balance sheet
date but before financial statements are issued. The adoption of SFAS&amp;#160;165
did not impact our financial position or results of operations. We evaluated
all events or transactions that occurred after June&amp;#160;30, 2009 up through
July&amp;#160;16, 2009, the date we issued these financial statements. During
this period we did not have any material recognizable subsequent events. However,
we did have a nonrecognizable subsequent event related to our collaboration
agreement with Cardiokine. Refer to Note 13, &lt;i&gt;Collaborations&lt;/i&gt;,
for additional information. &lt;/div&gt; &lt;div style="margin-top: 12pt;
font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;/div&gt; &lt;/body&gt; &lt;/html&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<!-- End Block Tagged Note --> <!-- Begin Block Tagged Note --> <us-gaap:InventoryDisclosureTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 2 - biib:InventoryTextBlock--&gt; &lt;div style="margin-left:
0%"&gt; &lt;table width="100%" border="0" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;tr&gt; &lt;td width="3%"&gt;&lt;/td&gt; &lt;td width="97%"&gt;&lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;2.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Inventory&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Inventories are stated at the lower of cost or market
with cost determined under the &lt;font style="white-space: nowrap"&gt;first-in,&lt;/font&gt;
first-out, or FIFO, method. Included in inventory are raw materials used in
the production of pre-clinical and clinical products, which are charged to
research and development expense when consumed. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; The components
of inventories are as follows (in millions): &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%"
align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family:
'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!--
Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="73%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;As of&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;As of&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom"
align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;June&amp;#160;30,&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;December&amp;#160;31,&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom"
align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:
3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Raw materials &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 38.8 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 29.8 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Work in process
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 173.4 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 180.0
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Finished goods &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
56.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 53.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 20pt"&gt;
Total Inventory &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 268.5 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 263.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Amounts written down related to unmarketable
inventory are charged to cost of product revenues, a component of total cost
of sales, excluding amortization of acquired intangible assets. During the
three and six months ended June&amp;#160;30, 2009 we have written-down $2.1&amp;#160;million
and $11.5&amp;#160;million, respectively, in unmarketable inventory as compared
to $5.5&amp;#160;million and $9.8&amp;#160;million, respectively, during the
prior year comparative periods. &lt;/div&gt; &lt;/div&gt; &lt;!-- END PAGE
WIDTH --&gt; &lt;!-- PAGEBREAK --&gt; &lt;div style="margin-left: 0%"&gt;
&lt;!-- BEGIN PAGE WIDTH --&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div align="center" style="margin-left:
0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/i&gt; &lt;/b&gt; &lt;/div&gt;
&lt;div style="margin-top: 18pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;/div&gt; &lt;/body&gt; &lt;/html&gt; </us-gaap:InventoryDisclosureTextBlock>
<!-- End Block Tagged Note --> <!-- Begin Block Tagged Note --> <biib:RevenueRecognitionTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 3 - us-gaap:RevenueRecognitionPolicyTextBlock--&gt; &lt;div style="margin-left:
0%"&gt; &lt;table width="100%" border="0" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;tr&gt; &lt;td width="3%"&gt;&lt;/td&gt; &lt;td width="97%"&gt;&lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;3.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Revenue Recognition&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;/table&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Product Revenues&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
We recognize revenue when all of the following criteria are met: persuasive
evidence of an arrangement exists; delivery has occurred or services have
been rendered; the seller&amp;#8217;s price to the buyer is fixed or determinable;
and collectibility is reasonably assured. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Revenues from
product sales are recognized when title and risk of loss have passed to the
customer, which is typically upon delivery. However, under the terms of a
development and marketing collaboration agreement with Elan Pharma International,
Ltd., or Elan, an affiliate of Elan Corporation, plc, we manufacture TYSABRI
and collaborate with Elan on the product&amp;#8217;s marketing, commercial
distribution and on-going development activities. Therefore, sales of TYSABRI
in the United States are recognized on the &amp;#8220;sell-through&amp;#8221;
model, that is, upon shipment of the product by Elan to its third party distributor
rather than upon shipment to Elan. For sales of TYSABRI outside the United
States, we are responsible for distributing TYSABRI to customers and are primarily
responsible for all operating activities. Generally, revenue on sales of TYSABRI
outside the United States is recognized at the time of product delivery to
our customers and distributors, as all revenue recognition criteria have been
met. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Reserves&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;i&gt;&lt;font style="font-family: 'Times
New Roman', Times"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/i&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Revenues are recorded net of applicable
allowances for trade term discounts, wholesaler incentives, Medicaid rebates,
Veteran&amp;#8217;s Administration rebates, managed care rebates, product
returns and other applicable allowances. Reserves established for these discounts
and allowances are classified as reductions of accounts receivable (if the
amount is payable to our customer) or a liability (if the amount is payable
to a party other than our customer). &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Our product revenue
reserves are based on estimates of the amounts earned or to be claimed on
the related sales. These estimates take into consideration our historical
experience, current contractual requirements, statutory requirements, specific
known market events and trends and forecasted customer buying patterns. If
actual results vary, we may need to adjust these estimates, which could have
an effect on earnings in the period of the adjustment. &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
An analysis of the amount of, and change in, reserves is as follows (in millions):
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;table border="0" width="100%" align="center" cellpadding="0"
cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt;
&lt;tr style="font-size: 1pt" valign="bottom"&gt; &lt;td width="60%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=lead --&gt; &lt;td width="5%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Contractual&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Discounts&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Adjustments&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;Returns&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;Total&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="line-height: 3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Beginning balance, as of January&amp;#160;1, 2009 &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 9.2
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
48.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
18.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
75.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt"&gt; Current provisions
relating to sales in current period &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 36.3
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 89.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 9.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 135.4 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
20pt"&gt; Adjustments relating to prior periods &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 3.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
3.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt"&gt; Payments/returns
relating to sales in current period &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (24.5
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(35.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (0.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (60.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; ) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 20pt"&gt; Payments/returns relating to sales in prior
periods &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; (8.1 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(46.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (8.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (63.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; ) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Ending balance, as of June&amp;#160;30, 2009 &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 12.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
58.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
18.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
90.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left: 0%; margin-right:
0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;/div&gt; &lt;!--
END PAGE WIDTH --&gt; &lt;!-- PAGEBREAK --&gt; &lt;div style="margin-left:
0%"&gt; &lt;!-- BEGIN PAGE WIDTH --&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div align="center" style="margin-left:
0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/i&gt; &lt;/b&gt; &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; The total reserves above were included in the consolidated
balance sheets as follows (in millions): &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%"
align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family:
'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!--
Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="78%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;As of&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;As of&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom"
align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;June&amp;#160;30,&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;December&amp;#160;31,&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom"
align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:
3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Reduction of accounts
receivable &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 38.8 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 31.6 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Current liability &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 51.2 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
43.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt"&gt; Total reserves &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
90.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
75.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Reserves for discounts, contractual adjustments
and returns reduced gross product revenues as follows (in millions): &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;table border="0" width="100%" align="center" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt; &lt;tr style="font-size:
1pt" valign="bottom"&gt; &lt;td width="58%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=lead --&gt; &lt;td width="5%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="5%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;For the&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Three
Months Ended&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Six Months Ended&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;June&amp;#160;30,&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;June&amp;#160;30,&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height: 3pt;
font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Discounts &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
19.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
15.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
36.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
30.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Contractual adjustments &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 50.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 35.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 92.7 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 72.2
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Returns &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
3.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 5.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 9.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 8.5 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 20pt"&gt; Total allowances &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 73.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
57.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
138.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 111.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Gross product revenues &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;864.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160;741.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1,663.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 1,460.6 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 10pt"&gt; Percent of gross product revenues &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
8.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; %
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 7.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
% &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 8.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
% &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 7.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
% &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left: 0%; margin-right:
0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div style="margin-top:
12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;i&gt;&lt;font style="font-family: 'Times
New Roman', Times"&gt;Bad Debt Reserves&lt;/font&gt;&lt;/i&gt; &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Bad debt reserves are based on our estimated uncollectible
accounts receivable. Given our historical experiences with bad debts, combined
with our credit management policies and practices, we do not presently maintain
significant bad debt reserves. Reserves for bad debts are reflected as a reduction
of accounts receivable. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;/div&gt; &lt;/body&gt; &lt;/html&gt; </biib:RevenueRecognitionTextBlock>
<!-- End Block Tagged Note --> <!-- Begin Block Tagged Note --> <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 4 - us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock--&gt;
&lt;div style="margin-left: 0%"&gt; &lt;table width="100%" border="0" cellpadding="0"
cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;tr&gt; &lt;td width="3%"&gt;&lt;/td&gt;
&lt;td width="97%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt;
&lt;b&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;4.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Intangible Assets and Goodwill&lt;/font&gt;&lt;/b&gt; &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Intangible assets and goodwill, net of accumulated
amortization, impairment charges and adjustments, are as follows (in millions):
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;table border="0" width="100%" align="center" cellpadding="0"
cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt;
&lt;tr style="font-size: 1pt" valign="bottom"&gt; &lt;td width="30%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=lead --&gt; &lt;td width="7%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="7%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="7%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="7%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=lead --&gt; &lt;td width="7%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=lead --&gt; &lt;td width="7%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=08 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=08 type=lead --&gt; &lt;td width="7%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=08 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=08 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;&amp;#160;&amp;#160;As of June&amp;#160;30,&amp;#160;&amp;#160;&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="10" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;As of December&amp;#160;31,&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="10" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Estimated&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Accumulated&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Accumulated&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
style="font-size: 7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Life&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Cost&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;Amortization&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Net&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Cost&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;Amortization&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Net&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:
3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -8pt; margin-left: 8pt"&gt;
Out-licensed patents &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 12&amp;#160;years
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
578.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (274.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 303.7 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 578.0 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (250.3
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 327.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -8pt; margin-left:
8pt"&gt; Core/developed technology &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 15-20&amp;#160;years
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 3,005.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (1,397.1 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1,608.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 3,005.3 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (1,241.0
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1,764.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-8pt; margin-left: 8pt"&gt; Trademarks and tradenames &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
Indefinite &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 64.0 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 64.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 64.0 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 64.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -8pt; margin-left:
8pt"&gt; In-licensed patents &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 14&amp;#160;years
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 3.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (1.0 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 2.0 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
3.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (0.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 2.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div
style="text-indent: -8pt; margin-left: 8pt"&gt; Assembled workforce &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 4&amp;#160;years &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 2.1 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(1.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 0.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 2.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (1.2 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
0.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -8pt; margin-left:
8pt"&gt; Distribution rights &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 2&amp;#160;years
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 12.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (12.7 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
12.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (10.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 2.1 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div
style="text-indent: -8pt; margin-left: 8pt"&gt; Total intangible assets &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 3,665.1 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;(1,686.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;1,978.5
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160;3,665.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160;(1,504.0 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;2,161.1 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-8pt; margin-left: 8pt"&gt; Goodwill &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; Indefinite
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160;1,138.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 1,138.6 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1,138.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1,138.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;/div&gt;
&lt;!-- END PAGE WIDTH --&gt; &lt;!-- PAGEBREAK --&gt; &lt;div style="margin-left:
0%"&gt; &lt;!-- BEGIN PAGE WIDTH --&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div align="center" style="margin-left:
0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/i&gt; &lt;/b&gt; &lt;/div&gt;
&lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 2%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Intangible
Assets&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Our intangible
assets consist of patents, licenses, core/developed technology, trademarks,
tradenames, assembled workforce, and distribution rights, the majority of
which arose in connection with the merger of Biogen Inc. and Idec Pharmaceuticals
Corporation, or the Merger. These intangible assets were recorded at fair
value and are stated net of accumulated amortization and impairments. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Intangible assets related to patents, licenses, core/developed
technology, assembled workforce, and distribution rights are amortized over
their remaining estimated useful lives, ranging from 2 to 20&amp;#160;years.
The useful lives of our assets are primarily based on the legal or contractual
life of the underlying patent or contract, which does not include additional
years for the extension or renewal of the contract or patent. Our amortization
policy for intangible assets is based on the principles in Statement of Financial
Accounting Standards No.&amp;#160;142, &lt;i&gt;Goodwill and Other Intangible
Assets&lt;/i&gt;, or SFAS&amp;#160;142, which requires that the amortization
of intangible assets reflect the pattern that the economic benefits of the
intangible assets are consumed. &lt;/div&gt; &lt;div style="margin-top: 6pt;
font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Effective January&amp;#160;1,
2009, we implemented FASB Staff Position (&amp;#8220;FSP&amp;#8221;) &lt;font
style="white-space: nowrap"&gt;FAS&amp;#160;142-3,&lt;/font&gt; &lt;i&gt;Determination
of the Useful Life of Intangible Assets&lt;/i&gt;, or FSP &lt;font style="white-space:
nowrap"&gt;FAS&amp;#160;142-3.&lt;/font&gt; FSP &lt;font style="white-space:
nowrap"&gt;FAS&amp;#160;142-3&lt;/font&gt; amends SFAS&amp;#160;142 and provides
guidance for determining the useful life of a recognized intangible asset
and requires enhanced disclosures so that users of financial statements are
able to assess the extent to which the expected future cash flows associated
with the asset are affected by our intent and ability to renew or extend the
arrangement. The adoption of this FSP did not impact our financial position
or results of operations as this standard was required to be implemented prospectively;
however, this standard may impact us in subsequent periods. &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
Our most significant intangible asset is the core technology related to our
AVONEX product. We believe the economic benefit of our core technology is
consumed as revenue is generated from our AVONEX product. An analysis of the
anticipated product sales of AVONEX is performed annually during our long
range planning cycle. The results of this forecast serve as the basis for
our assumptions used in the economic consumption amortization model for our
core technology intangible assets. Although we believe our process has allowed
us to reliably determine our best estimate of the pattern in which we will
consume the economic benefits of the core technology intangible assets, the
model could result in deferring amortization charges to future periods in
certain instances, including the impact of continued sales of the product
at a nominal level after patent expiration. Consequently, in establishing
our methodology, we considered models that would prevent deferring amortization
charges to future periods such as the model described in paragraph&amp;#160;8
of Statement of Financial Accounting Standards No.&amp;#160;86, &lt;i&gt;Accounting
for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed&lt;/i&gt;,
or SFAS&amp;#160;86. In order to ensure amortization charges are not unreasonably
deferred to future periods, we use the straight-line method to determine the
minimum annual amount of amortization expense, or the minimum amount. At the
time of the Merger we estimated a useful life of 15&amp;#160;years (2018)
based on the patent lives of AVONEX across various countries. The minimum
amount is recalculated each year based on the remaining unamortized balance
of the intangible asset and the years remaining to 2018. The results of the
long range planning process determine whether amortization will be based on
an economic consumption model or the minimum amount and, thus, the amount
of amortization for the next four quarters. Amortization is currently based
upon the economic consumption model. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Intangible assets
related to trademarks and tradenames have indefinite lives, and as a result
are not amortized, but are subject to review for impairment. We review our
intangible assets with indefinite lives for impairment annually, as of October&amp;#160;31,
and whenever events or changes in circumstances indicate that the carrying
value of an asset may not be recoverable. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Amortization expense
was $93.2&amp;#160;million and $182.5&amp;#160;million for the three months
and six months ended June&amp;#160;30, 2009, respectively, as compared to
$72.9&amp;#160;million and $147.7&amp;#160;million, respectively, for the
prior year comparative periods. We did not record a charge related to acquired
in-process research and development, or IPR&amp;#038;D, during the three and
six months ended June&amp;#160;30, 2009, respectively, or during the three
months ended June&amp;#160;30, 2008. In the first quarter of 2008, we recorded
an IPR&amp;#038;D charge of $25.0&amp;#160;million related to a HSP90-related
milestone payment made to the former shareholders of Conforma Therapeutics,
Inc., or Conforma, pursuant to the terms of our acquisition of Conforma in
2006. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;/div&gt; &lt;/body&gt; &lt;/html&gt; </us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
<!-- End Block Tagged Note --> <!-- Begin Block Tagged Note --> <us-gaap:FairValueDisclosuresTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 5 - us-gaap:FairValueDisclosuresTextBlock--&gt; &lt;div style="margin-left:
0%"&gt; &lt;table width="100%" border="0" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;tr&gt; &lt;td width="3%"&gt;&lt;/td&gt; &lt;td width="97%"&gt;&lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;5.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Fair Value Measurements&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;/table&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Effective January&amp;#160;1, 2008, we implemented
Statement of Financial Accounting Standards No.&amp;#160;157, &lt;i&gt;Fair
Value Measurements&lt;/i&gt;, or SFAS&amp;#160;157, for financial assets and
liabilities that are remeasured and reported at fair value at each reporting
period, and non-financial assets and liabilities that are remeasured and reported
at fair value at least annually. In accordance with the provisions of FSP
&lt;font style="white-space: nowrap"&gt;FAS&amp;#160;157-2,&lt;/font&gt; &lt;i&gt;Effective
Date of FASB Statement No.&amp;#160;157&lt;/i&gt;, we elected to defer until
January&amp;#160;1, 2009 implementation of SFAS&amp;#160;157 as it relates
to our non-financial assets and liabilities that are recognized and disclosed
at fair value in the financial statements on a non-recurring basis. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; The adoption of SFAS&amp;#160;157 for our non-financial
assets and liabilities that are remeasured at fair value on a non-recurring
basis did not have a material impact on our financial position or results
of operations upon adoption; however, this standard may impact us in subsequent
periods and require additional disclosures. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Effective this
quarter, we implemented FSP &lt;font style="white-space: nowrap"&gt;FAS&amp;#160;157-4,&lt;/font&gt;
&lt;i&gt;Determining Fair Value When the Volume and Level of Activity for
the Asset or Liability Have Significantly Decreased and Identifying Transactions
That Are Not Orderly&lt;/i&gt;, or FSP &lt;font style="white-space: nowrap"&gt;FAS&amp;#160;157-4.&lt;/font&gt;
FSP &lt;font style="white-space: nowrap"&gt;FAS&amp;#160;157-4&lt;/font&gt;
provides additional guidelines for making fair value measurements more consistent
with the principles presented in SFAS&amp;#160;157 and provides authoritative
guidance in determining whether a market is active or inactive, and whether
a transaction is distressed. This FSP is applicable to all assets and liabilities
(i.e. financial and nonfinancial) and requires enhanced disclosures, including
interim and annual disclosure of the input and valuation techniques (or changes
in techniques) used to measure fair value and the defining of the major security
types comprising debt and equity securities held based upon the nature and
risk of the security. The adoption of this FSP did not impact our financial
position or results of operations; however, adoption has enhanced disclosures
for our investments in marketable debt securities and resulted in the reclassification
of certain amounts included within our previously reported disclosures to
conform to the presentation adopted in the current year. &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
Effective this quarter, we have also implemented FSP &lt;font style="white-space:
nowrap"&gt;FAS&amp;#160;107-1&lt;/font&gt; and APB &lt;font style="white-space:
nowrap"&gt;28-1,&lt;/font&gt; &lt;i&gt;Interim Disclosures about Fair Value
of Financial Instruments&lt;/i&gt;, or FSP &lt;font style="white-space: nowrap"&gt;FAS&amp;#160;107-1.&lt;/font&gt;
FSP &lt;font style="white-space: nowrap"&gt;FAS&amp;#160;107-1&lt;/font&gt;
amended Statement of Financial Accounting Standards No.&amp;#160;107, &lt;i&gt;Disclosures
about Fair Value of Financial Instruments&lt;/i&gt;, and APB Opinion No.&amp;#160;28,
&lt;i&gt;Interim Financial Reporting&lt;/i&gt;, to require disclosures about
the fair value of financial instruments in interim as well as in annual financial
statements. The adoption of this standard has resulted in the disclosure of
the fair values attributable to our debt instruments within our interim report.
Since this FSP addresses disclosure requirements, the adoption of this FSP
did not impact our financial position or results of operations. &lt;/div&gt;
&lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 2%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Summary
of Assets and Liabilities Recorded at Fair Value&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; The tables below present information about
our assets and liabilities that are measured at fair value on a recurring
basis as of June&amp;#160;30, 2009 and December&amp;#160;31, 2008 and indicate
the fair value hierarchy of the valuation techniques we utilized to determine
such fair value. In general, fair values determined by Level&amp;#160;1 inputs
utilize quoted prices (unadjusted) in active markets for identical assets
or liabilities. Fair values determined by Level&amp;#160;2 inputs utilize
data points that are observable such as quoted prices, interest rates and
yield curves. Fair values determined by Level&amp;#160;3 inputs utilize unobservable
data points for the asset or liability. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; A majority of
our financial assets and liabilities have been classified as Level&amp;#160;2.
These assets and liabilities have been initially valued at the transaction
price and subsequently valued typically utilizing third party pricing services.
The pricing services use many inputs to determine value, including reportable
trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers,
current spot rates, other industry, and economic events. We validate the prices
provided by our third party pricing services by reviewing their pricing methods
and matrices, obtaining market values from other pricing sources, and analyzing
pricing data in certain instances. The fair values of our cash equivalents,
derivative contracts, marketable debt securities, and plan assets for deferred
compensation are determined through market and observable sources and have
been classified as Level&amp;#160;2. After completing our validation procedures,
we did not adjust or override any fair value measurements provided by our
pricing services as of June&amp;#160;30, 2009 and December&amp;#160;31, 2008.
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; The following tables set forth our financial
assets and liabilities that were recorded at fair value (in millions): &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;table border="0" width="100%" align="center" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt; &lt;tr style="font-size:
1pt" valign="bottom"&gt; &lt;td width="38%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="12%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="13%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Significant&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Balance as of&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Quoted
Prices in&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Significant Other&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Unobservable&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;June&amp;#160;30,&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Active Markets&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Observable
Inputs&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Inputs&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom"
align="center"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="border-bottom: 1px solid #000000; width: 1%; padding-bottom:
1px"&gt; &lt;b&gt;Description&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;(Level 1)&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;(Level 2)&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;(Level 3)&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="line-height: 3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Assets: &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Cash equivalents &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 670.3
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 670.3
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Marketable debt securities: &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 20pt"&gt; Corporate debt securities &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
412.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 412.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt"&gt; Government securities
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 1,267.5 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1,267.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt"&gt; Mortgage and other
asset backed securities &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 203.8 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 203.8 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Strategic investments &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
5.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 5.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Venture capital
investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 21.6 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 21.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Derivative contracts &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
0.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 0.3 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Plan assets for deferred compensation &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
11.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 11.9 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 10pt"&gt; Total &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 2,593.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
5.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
2,566.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 21.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Liabilities: &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Derivative contracts &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
31.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 31.8 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 31.8 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
31.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div
style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table
border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;!-- Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="38%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="12%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="13%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Significant&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Balance as of&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Quoted
Prices in&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Significant Other&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Unobservable&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;December&amp;#160;31,&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Active Markets&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Observable Inputs&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Inputs&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="border-bottom: 1px solid #000000; width:
1%; padding-bottom: 1px"&gt; &lt;b&gt;Description&lt;/b&gt; &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;(Level 1)&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;(Level 2)&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;(Level 3)&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="line-height: 3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Assets: &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Cash equivalents &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 500.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 500.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Marketable debt securities: &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 20pt"&gt; Corporate debt securities &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
328.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 328.5
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt"&gt; Government securities
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 1,005.0 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1,005.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt"&gt; Mortgage and other
asset backed securities &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 306.9 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 306.9 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Strategic investments &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
4.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 4.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Venture capital
investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 23.9 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 23.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Derivative contracts &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1.9 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Plan assets for deferred compensation &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
13.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 13.3 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 10pt"&gt; Total &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 2,185.0
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
4.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
2,156.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 23.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Liabilities: &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Derivative contracts &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
46.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 46.0 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 46.0 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
46.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;/div&gt;
&lt;!-- END PAGE WIDTH --&gt; &lt;!-- PAGEBREAK --&gt; &lt;div style="margin-left:
0%"&gt; &lt;!-- BEGIN PAGE WIDTH --&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div align="center" style="margin-left:
0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/i&gt; &lt;/b&gt; &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Our strategic investments are investments in publicly
traded equity securities where fair value is readily determinable. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; The following table provides a roll forward of the
fair value of our venture capital investments, where fair value is determined
by Level&amp;#160;3 inputs (in millions): &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%"
align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family:
'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!--
Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="61%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="5%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="5%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="5%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="5%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the Three Months&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;For the Six Months&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Ended June&amp;#160;30,&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Ended June&amp;#160;30,&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="border-bottom: 1px solid #000000; width: 1%; padding-bottom:
1px"&gt; &lt;b&gt;Description&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height: 3pt;
font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Beginning Balance
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160;&amp;#160;24.3 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;&amp;#160;24.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160;&amp;#160;23.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160;&amp;#160;28.1 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 20pt"&gt; Total net unrealized gains (losses) included
in earnings &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; (2.8 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(1.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (3.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (4.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 20pt"&gt; Purchases, issuances, and settlements &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 0.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 0.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 0.8 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Ending Balance &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 21.6 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 24.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
21.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
24.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left: 0%; margin-right:
0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Our venture capital
investments are the only assets where we used Level&amp;#160;3 inputs to determine
the fair value. Venture capital investments represented approximately 0.2%
and 0.3% of total assets as of June&amp;#160;30, 2009 and December&amp;#160;31,
2008, respectively. The underlying assets in these funds are initially measured
at transaction prices and subsequently valued using the pricing of recent
financing or by reviewing the underlying economic fundamentals and liquidation
value of the companies. Gains and losses (realized and unrealized) included
in earnings for the period are reported in other income (expense), net. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; The carrying amounts reflected in the consolidated
balance sheets for cash, accounts receivable, due from unconsolidated joint
business, other current assets, accounts payable, accrued expenses, and other
approximate fair value due to their short-term nature. &lt;/div&gt; &lt;div
style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family:
Arial, Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font
style="font-family: 'Times New Roman', Times"&gt;Summary of Liabilities Recorded
at Carrying Value&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; The fair and carrying
value of our debt instruments are detailed as follows (in millions): &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;table border="0" width="100%" align="center" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt; &lt;tr style="font-size:
1pt" valign="bottom"&gt; &lt;td width="57%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;As of June&amp;#160;30, 2009&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;As of December&amp;#160;31, 2008&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Fair&lt;br /&gt;
&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Carrying&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Fair&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Carrying&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;Value&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height: 3pt;
font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 10pt"&gt; Credit line from Domp&amp;#233;
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 16.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 16.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 16.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 16.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Notes payable to Fumedica &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 28.8 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
28.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 37.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 38.5 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; 6.0%&amp;#160;Senior
Notes due 2013 &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 458.7 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
449.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 429.8 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 449.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; 6.875%&amp;#160;Senior
Notes due 2018 &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 561.6 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
605.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 562.4 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 608.2
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 20pt"&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1,065.7 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1,100.3
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1,046.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1,113.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
The fair values of our debt instruments were estimated using market observable
inputs, including quoted prices in active markets, market indices and interest
rate measurements. Within the hierarchy of fair value measurements, these
are Level&amp;#160;2 fair values. &lt;/div&gt; &lt;div style="margin-top:
12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;/div&gt; &lt;/body&gt;
&lt;/html&gt; </us-gaap:FairValueDisclosuresTextBlock> <!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note --> <biib:FinancialInstrumentsTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 6 - biib:FinancialInstrumentsTextBlock--&gt; &lt;div style="margin-left:
0%"&gt; &lt;table width="100%" border="0" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;tr&gt; &lt;td width="3%"&gt;&lt;/td&gt; &lt;td width="97%"&gt;&lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;6.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Financial Instruments&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;/table&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Financial instruments that potentially subject
us to concentrations of credit risk are accounts receivable and marketable
securities. The majority of our accounts receivable are payable by wholesale
distributors and large pharmaceutical companies and collateral is generally
not required from these large customers. We monitor the financial performance
and credit worthiness of our large customers so that we can properly assess
and respond to changes in their credit profile. Our portfolio of marketable
securities is subject to concentration limits set within our investment policy
that help to mitigate our credit exposure. &lt;/div&gt; &lt;/div&gt; &lt;!--
END PAGE WIDTH --&gt; &lt;!-- PAGEBREAK --&gt; &lt;div style="margin-left:
0%"&gt; &lt;!-- BEGIN PAGE WIDTH --&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div align="center" style="margin-left:
0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/i&gt; &lt;/b&gt; &lt;/div&gt;
&lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 2%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Marketable
Securities, including Strategic Investments&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; The following is a summary of our marketable
securities and strategic investments (in millions): &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%"
align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family:
'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!--
Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="57%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Gross&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Gross&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Fair&lt;br /&gt;
&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Unrealized&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Unrealized&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Amortized&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="border-bottom: 1px solid #000000;
width: 1%; padding-bottom: 1px"&gt; &lt;b&gt;As of June&amp;#160;30, 2009:&lt;/b&gt;
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Gains&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Losses&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;Cost&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="line-height: 3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; &lt;i&gt;Available-for-sale&lt;/i&gt; &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Corporate debt securities &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt"&gt; Current &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
189.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 188.2
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
20pt"&gt; Non-current &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 222.7 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
5.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (0.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 217.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Government securities
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 20pt"&gt;
Current &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 642.1 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 640.2 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 20pt"&gt; Non-current &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
625.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 6.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (0.3 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
619.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Mortgage and other asset backed securities &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt"&gt; Current &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 4.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 0.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
4.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
20pt"&gt; Non-current &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 199.5 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
5.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 194.0 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid
#000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 20pt"&gt; Total available-for-sale
securities &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 1,883.9 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 20.7 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (0.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1,863.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; &lt;i&gt;Other Investments&lt;/i&gt;
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Strategic investments, non-current &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 5.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
2.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 3.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div
style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table
border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;!-- Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="57%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Gross&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Gross&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Fair&lt;br /&gt;
&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Unrealized&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Unrealized&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Amortized&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="border-bottom: 1px solid #000000;
width: 1%; padding-bottom: 1px"&gt; &lt;b&gt;As of December&amp;#160;31, 2008:&lt;/b&gt;
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Gains&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Losses&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;Cost&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="line-height: 3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; &lt;i&gt;Available-for-sale&lt;/i&gt; &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Corporate debt securities &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt"&gt; Current &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
128.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;0.4
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 127.8
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
20pt"&gt; Non-current &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 200.3 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
2.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 197.7 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Government securities &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 20pt"&gt; Current &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
582.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 1.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
581.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 20pt"&gt; Non-current &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 422.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 8.7 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 413.5 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Mortgage and other asset backed securities &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 20pt"&gt;
Current &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 13.9 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 13.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
20pt"&gt; Non-current &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 293.0 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
3.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (0.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 290.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 20pt"&gt; Total available-for-sale securities &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1,640.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 16.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (0.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1,624.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
&lt;i&gt;Other Investments&lt;/i&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Strategic investments, non-current &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
4.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
0.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(0.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
4.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left: 0%; margin-right:
0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; In the tables
above, as of June&amp;#160;30, 2009 and December&amp;#160;31, 2008, government
securities included $274.8&amp;#160;million and $139.1&amp;#160;million, respectively,
of Federal Deposit Insurance Corporation, or FDIC, guaranteed senior notes
issued by financial institutions under the Temporary Liquidity Guarantee Program.
In addition, the balances as of December&amp;#160;31, 2008 include amounts
related to our loaned securities. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; As of June&amp;#160;30,
2009, we held mortgage and other asset backed securities totaling $203.8&amp;#160;million.
No &lt;font style="white-space: nowrap"&gt;non-agency&lt;/font&gt; mortgage
backed securities were held as of June&amp;#160;30, 2009. As of December&amp;#160;31,
2008, we held total mortgage and other asset backed securities totaling $306.8&amp;#160;million,
which included $66.5&amp;#160;million of &lt;font style="white-space: nowrap"&gt;non-agency&lt;/font&gt;
mortgage backed securities. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; Certain commercial
paper and short-term debt securities with original maturities of less than
90&amp;#160;days are included in cash and cash equivalents on the accompanying
balance sheet and are not included in the tables above. As of June&amp;#160;30,
2009 and December&amp;#160;31, 2008, the commercial paper, including accrued
interest, has a fair and carrying value of $115.1&amp;#160;million and $42.7&amp;#160;million,
respectively, and short-term debt securities have a fair and carrying value
of $555.2&amp;#160;million and $458.2&amp;#160;million, respectively. &lt;/div&gt;
&lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 2%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Summary
of Contractual Maturities: Available-for-Sale Securities&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; The estimated fair value and amortized cost
of securities, excluding strategic investments, available-for-sale by contractual
maturity as of June&amp;#160;30, 2009 and December&amp;#160;31, 2008 were
as follows (in millions): &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%" align="center"
cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!-- Table
Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt; &lt;td
width="57%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata --&gt;
&lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;As of June&amp;#160;30, 2009&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;As of December&amp;#160;31, 2008&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Estimated&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Amortized&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Estimated&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Amortized&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Fair Value&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Cost&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;Fair Value&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Cost&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:
3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Due in one year
or less &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 713.5 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 710.3 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 714.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
713.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Due after one year through five years &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1,027.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 1,013.5 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 733.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 722.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 10pt"&gt; Due after five years &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 143.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 140.1 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
191.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 189.2 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 20pt"&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1,883.9 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1,863.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1,640.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1,624.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
The average maturity of our marketable securities as of June&amp;#160;30,
2009 and December&amp;#160;31, 2008, was 15&amp;#160;months and 13&amp;#160;months,
respectively. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Impairments&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family:
Arial, Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;i&gt;&lt;font
style="font-family: 'Times New Roman', Times"&gt;Other-than-Temporary Impairments&lt;/font&gt;&lt;/i&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; In April 2009, the FASB issued FSP &lt;font
style="white-space: nowrap"&gt;No.&amp;#160;FAS&amp;#160;115-2&lt;/font&gt;
and &lt;font style="white-space: nowrap"&gt;FAS&amp;#160;124-2,&lt;/font&gt;
&lt;i&gt;Recognition and Presentation of Other-than-Temporary Impairments&lt;/i&gt;,
or FSP &lt;font style="white-space: nowrap"&gt;FAS&amp;#160;115-2,&lt;/font&gt;
which amended the other-than-temporary impairment model for debt securities.
The impairment model for equity securities was not affected. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Under this FSP, an other-than-temporary impairment
must be recognized through earnings if an investor has the intent to sell
the debt security or if it is more likely than not that the investor will
be required to sell the debt security before recovery of its amortized cost
basis. However, even if an investor does not expect to sell a debt security,
it must evaluate expected cash flows to be received and determine if a credit
loss has occurred. In the event of a credit loss, only the amount associated
with the credit loss is recognized in income. The amount of loss relating
to other factors is recorded in accumulated other comprehensive income. The
FSP also requires additional disclosures regarding the calculation of credit
losses and the factors considered in reaching a conclusion that an investment
is not other-than-temporarily impaired. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; We adopted the
provisions of FSP &lt;font style="white-space: nowrap"&gt;FAS&amp;#160;115-2&lt;/font&gt;
on April&amp;#160;1, 2009. The adoption of the FSP did not have a material
impact on our financial position or results of operations. &lt;/div&gt; &lt;div
style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family:
Arial, Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;i&gt;&lt;font
style="font-family: 'Times New Roman', Times"&gt;Evaluating Investments for
Other-than-Temporary Impairments&lt;/font&gt;&lt;/i&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
We conduct periodic reviews to identify and evaluate each investment that
has an unrealized loss, in accordance with FSP &lt;font style="white-space:
nowrap"&gt;FAS&amp;#160;115-1,&lt;/font&gt; &lt;i&gt;The Meaning of Other-than-Temporary
Impairment and its Application to Certain Investments, &lt;/i&gt;or FSP FAS
&lt;font style="white-space: nowrap"&gt;115-1,&lt;/font&gt; and FSP &lt;font
style="white-space: nowrap"&gt;FAS&amp;#160;115-2.&lt;/font&gt; An unrealized
loss exists when the current fair value of an individual security is less
than its amortized cost basis. Unrealized losses on available-for-sale securities
that are determined to be temporary, and not related to credit loss, are recorded,
net of tax, in accumulated other comprehensive income. &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
For available-for-sale debt securities with unrealized losses, management
performs an analysis to assess whether we intend to sell or whether we would
more likely than not be required to sell the security before the expected
recovery of the amortized cost basis. Where we intend to sell a security,
or may be required to do so, the security&amp;#8217;s decline in fair value
is deemed to be other-than-temporary and the full amount of the unrealized
loss is recorded within earnings as an impairment loss. &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
Regardless of our intent to sell a security, we perform additional analysis
on all securities with unrealized losses to evaluate losses associated with
the creditworthiness of the security. Credit losses are identified where we
do not expect to receive cash flows sufficient to recover the amortized cost
basis of a security. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; For equity securities,
when assessing whether a decline in fair value below our cost basis is other-than-temporary,
we consider the fair market value of the security, the duration of the security&amp;#8217;s
decline, and the financial condition of the issuer. We then consider our intent
and ability to hold the equity security for a period of time sufficient to
recover our carrying value. Where we have determined that we lack the intent
and ability to hold an equity security to its expected recovery, the security&amp;#8217;s
decline in fair value is deemed to be other-than-temporary and is recorded
within earnings as an impairment loss. &lt;/div&gt; &lt;div style="margin-top:
12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;i&gt;&lt;font style="font-family: 'Times
New Roman', Times"&gt;Recognition and Measurement of Other-than-Temporary
Impairment&lt;/font&gt;&lt;/i&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Prior to our adoption
of FSP &lt;font style="white-space: nowrap"&gt;FAS&amp;#160;115-2&lt;/font&gt;
in the current quarter, we recognized impairments under the previously effective
guidance contained within SFAS&amp;#160;115, &lt;i&gt;Accounting for Certain
Investments in Debt and Equity Securities.&lt;/i&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
No impairment losses were recognized through earnings related to available
for sale securities during the three months ended June&amp;#160;30, 2009.
During the six months ended June&amp;#160;30, 2009, we recognized $3.6&amp;#160;million
in charges for the impairment of available for sale securities primarily related
to mortgage and asset backed securities when we lacked the ability and intent
to hold the securities to recovery. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; For the three
and six months ended June&amp;#160;30, 2008, we recognized $2.9&amp;#160;million
and $5.2&amp;#160;million, respectively, in charges for the other-than-temporary
impairment of available-for-sale securities primarily related to mortgage
and asset backed securities. &lt;/div&gt; &lt;div style="margin-top: 6pt;
font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; During the three
months ended June&amp;#160;30, 2009, we recognized in other comprehensive
income, before tax unrealized losses of $0.7&amp;#160;million. &lt;/div&gt;
&lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 2%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Strategic
Investments&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; We hold investments
in equity securities of certain publicly traded companies. These strategic
investments are included in investments and other assets on the accompanying
consolidated balance sheet. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; No impairment losses
were recognized related to our strategic investments during the three months
ended June&amp;#160;30, 2009. During the six months ended June&amp;#160;30,
2009 we recognized charges totaling $0.4&amp;#160;million for the impairment
of strategic investments that were determined to be &lt;font style="white-space:
nowrap"&gt;other-than-temporary.&lt;/font&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; For the three
and six months ended June&amp;#160;30, 2008, we recognized $0.9&amp;#160;million
and $3.6&amp;#160;million, respectively, in charges for the impairment of
strategic investments that were determined to be &lt;font style="white-space:
nowrap"&gt;other-than-temporary.&lt;/font&gt; &lt;/div&gt; &lt;div style="margin-top:
12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;Non-Marketable Securities&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; We hold investments in equity securities
of certain privately held biotechnology companies and biotechnology oriented
venture capital funds. The carrying value of these securities as of June&amp;#160;30,
2009 and December&amp;#160;31, 2008, was $92.5&amp;#160;million and $64.7&amp;#160;million,
respectively. These securities are included in investments and other assets
on the accompanying consolidated balance sheet. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; For the three
and six months ended June&amp;#160;30, 2009, we recognized unrealized losses
of $2.8&amp;#160;million and $3.1&amp;#160;million, respectively, due to declines
in the fair value of the investments in venture capital funds, as compared
to $1.2&amp;#160;million and $4.8&amp;#160;million, respectively, during the
comparable period in the prior year. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; We recognized
charges for the impairment of investments in privately held companies or funds
that were determined to be &lt;font style="white-space: nowrap"&gt;other-than-temporary&lt;/font&gt;
during the three and six month periods ended June&amp;#160;30, 2009 of $0.5&amp;#160;million
and $1.9&amp;#160;million, respectively. Charges for the impairment of investments
in privately held companies or funds that were determined to be &lt;font style="white-space:
nowrap"&gt;other-than-temporary&lt;/font&gt; were recognized during the three
and six month periods ended June&amp;#160;30, 2008 in the amount of $1.0&amp;#160;million,
respectively. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Proceeds from Marketable Securities, excluding Strategic Investments&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; The proceeds from maturities and sales of
marketable securities, excluding strategic investments, which were primarily
reinvested and resulting realized gains and losses, were as follows (in millions):
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;table border="0" width="100%" align="center" cellpadding="0"
cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt;
&lt;tr style="font-size: 1pt" valign="bottom"&gt; &lt;td width="53%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="7%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the Three Months&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;Ended June&amp;#160;30,&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;For the Six Months Ended June&amp;#160;30,&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height: 3pt; font-size: 1pt"&gt;
&lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Proceeds from maturities and sales &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160;&amp;#160;579.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;&amp;#160;473.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1,637.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1,391.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Realized gains &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 8.2
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
13.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
10.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Realized losses &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 0.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
0.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
2.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
4.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
The realized losses for the three and six months ended June&amp;#160;30, 2009
and 2008 primarily relate to losses on the sale of corporate debt securities
and non-agency mortgage-backed securities. &lt;/div&gt; &lt;div style="margin-top:
12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;Securities Lending&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; We have previously loaned certain securities
from our portfolio to other institutions. Such securities are classified as
loaned securities on the accompanying consolidated balance sheet. Collateral
for the loaned securities, consisting of cash or other securities is maintained
at a rate of approximately 102% of the market value of each loaned security.
We held collateral in the amount of $30.0&amp;#160;million as of December&amp;#160;31,
2008. The cash collateral was recorded as collateral received for loaned securities
on the accompanying consolidated balance sheet. No such loans were outstanding
as of June&amp;#160;30, 2009 and accordingly no collateral was held as of
June&amp;#160;30, 2009. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 2%;
margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000;
background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times
New Roman', Times"&gt;Forward Contracts and Interest Rate Swaps&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Effective January&amp;#160;1, 2009, we implemented
Statement of Financial Accounting Standards No.&amp;#160;161&lt;i&gt;, Disclosures
About Derivative Instruments and Hedging Activities, &lt;/i&gt;or SFAS&amp;#160;161.
As a result of adopting this standard we have provided additional information
about our objectives for using derivative instruments, the level of derivative
activity we engage in, and the effect of derivative instruments and related
hedged items on our financial position and performance. The adoption of SFAS&amp;#160;161
did not affect our financial position or results of operations. &lt;/div&gt;
&lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 2%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Forward
Contracts&lt;/font&gt;&lt;/i&gt; &lt;/div&gt; &lt;div style="margin-top: 6pt;
font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Due to the global
nature of our operations, portions of our revenues are in currencies other
than the U.S.&amp;#160;dollar. The value of revenue measured in U.S.&amp;#160;dollars
is subject to changes in currency exchange rates. In order to mitigate these
changes we use forward contracts to lock in exchange rates. We do not engage
in currency speculation. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; All foreign currency
forward contracts in effect as of June&amp;#160;30, 2009 and December&amp;#160;31,
2008 had durations of 1 to 12&amp;#160;months. These contracts have been designated
as cash flow hedges and accordingly, to the extent effective, any unrealized
gains or losses on these foreign currency forward contracts are reported in
accumulated other comprehensive income (loss). Realized gains and losses for
the effective portion of such contracts are recognized in revenue with the
completion of the underlying hedged transaction. To the extent ineffective,
hedge transaction gains and losses are reported in other income (expense)
at each reporting date. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; Foreign currency forward
contracts that were entered into to hedge forecasted revenue were as follows
(in millions): &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;table border="0" width="100%" align="center" cellpadding="0"
cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt;
&lt;tr style="font-size: 1pt" valign="bottom"&gt; &lt;td width="63%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=lead --&gt; &lt;td width="14%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="14%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Notional Amount&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom"
align="center"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;As of June&amp;#160;30,&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;As of December&amp;#160;31,&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom"
align="center"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="border-bottom: 1px solid #000000; width: 1%; padding-bottom:
1px"&gt; &lt;b&gt;Foreign Currency:&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height: 3pt; font-size: 1pt"&gt;
&lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 10pt"&gt; Euro &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;&amp;#160;379.5
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160;&amp;#160;489.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Canadian Dollar &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
32.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 34.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 20pt"&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 412.3 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 523.5
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; The notional settlement amount of the foreign
currency forward contracts outstanding as of June&amp;#160;30, 2009 was approximately
$412.3&amp;#160;million. The portion of the fair value of these contracts
that was included in accumulated other comprehensive income (loss) within
total equity was a $31.7&amp;#160;million loss as of June&amp;#160;30, 2009.
We consider the impact of our and our counterparties&amp;#8217; credit risk
on the fair value of the contracts as well as the ability of each party to
execute its obligations under the contract. As of June&amp;#160;30, 2009,
credit risk did not materially change the fair value of our foreign currency
forward contracts. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; The notional settlement
amount of the foreign currency forward contracts outstanding as of December&amp;#160;31,
2008 was approximately $523.5&amp;#160;million and the fair value of these
contracts resulted in a net unrealized loss of $44.1&amp;#160;million which
was included in accumulated other comprehensive income (loss) within total
equity. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; In relation to our foreign currency forward
contracts, we recognized net gains of $1.7&amp;#160;million and net losses
of $0.8&amp;#160;million, respectively, in earnings due to hedge ineffectiveness,
during the three and six months ended June&amp;#160;30, 2009, as compared
to net losses of $0.5&amp;#160;million and $1.2&amp;#160;million, respectively,
during the prior year comparative periods. We recognized $9.2&amp;#160;million
and $12.3&amp;#160;million, respectively, of losses in product revenue for
the settlement of certain effective cash flow hedge instruments for the three
and six months ended June&amp;#160;30, 2009 as compared to losses recognized
in the amount of $10.1&amp;#160;million and $17.7&amp;#160;million, respectively,
during the prior year comparative periods. These settlements were recorded
in the same period as the related forecasted revenue. &lt;/div&gt; &lt;div
style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family:
Arial, Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;i&gt;&lt;font
style="font-family: 'Times New Roman', Times"&gt;Interest Rate Swaps&lt;/font&gt;&lt;/i&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; In connection with the issuance of our 6.0%
and 6.875%&amp;#160;Senior Notes in March 2008, we entered into interest rate
swaps for an aggregate notional amount of $550.0&amp;#160;million, which were
subsequently settled in December 2008. Under the settlement we received $53.9&amp;#160;million.
As the interest rate swaps were settled in 2008, no hedge ineffectiveness
was recognized for the three and six months ended June&amp;#160;30, 2009.
Net losses due to hedge ineffectiveness of $3.7 and $5.0&amp;#160;million
were recognized in earnings for the three and six months ended June&amp;#160;30,
2008, respectively. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; Additionally, upon
termination of the swaps in December 2008, the carrying amount of the 6.875%&amp;#160;Senior
Notes increased $62.8&amp;#160;million. This amount will be recognized as
a reduction of interest expense and amortized using the effective interest
rate method over the remaining life of the 6.875%&amp;#160;Senior Notes. During
the three and six months ended June&amp;#160;30, 2009, approximately $1.3&amp;#160;million
and $2.6&amp;#160;million, respectively, was recorded as a reduction of interest
expense. &lt;/div&gt; &lt;/div&gt; &lt;!-- END PAGE WIDTH --&gt; &lt;!-- PAGEBREAK
--&gt; &lt;div style="margin-left: 0%"&gt; &lt;!-- BEGIN PAGE WIDTH --&gt;
&lt;div style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt; &lt;div align="center"
style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial,
Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div
style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt; &lt;div align="center"
style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial,
Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div
align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt;
font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt;
&lt;i&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt; &lt;/font&gt;
&lt;/i&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 2%;
margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000;
background: #FFFFFF"&gt; &lt;i&gt;&lt;font style="font-family: 'Times New
Roman', Times"&gt;Summary of Derivatives designated as Hedging Instruments&lt;/font&gt;&lt;/i&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; The following table summarizes the fair
value and presentation in the consolidated balance sheets for derivatives
designated as hedging instruments under Statement of Financial Accounting
Standards No.&amp;#160;133, &lt;i&gt;Accounting for Derivative Instruments
and Hedging Activities&lt;/i&gt;, or SFAS&amp;#160;133, as of June&amp;#160;30,
2009 and December&amp;#160;31, 2008, respectively (in millions): &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;table border="0" width="100%" align="center" cellpadding="0" cellspacing="0"
style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt; &lt;tr style="font-size:
1pt" valign="bottom"&gt; &lt;td width="28%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="16%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=maindata --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="11%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="23%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=maindata --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="12%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="10" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Foreign Currency Contracts&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="4"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;Asset Derivatives&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="4" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Liability Derivatives&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Balance
Sheet&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Balance
Sheet&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Location&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Fair Value&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Location&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Fair Value&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:
3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; June&amp;#160;30,
2009 &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td align="left"
valign="bottom"&gt; Other current assets &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td align="left" valign="bottom"&gt;
Accrued expenses and other &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 31.8 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; December&amp;#160;31,
2008 &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td align="left"
valign="bottom"&gt; Other current assets &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; 1.9 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td align="left" valign="bottom"&gt;
Accrued expenses and other &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 46.0 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; As noted above, the
interest rate swaps were settled in December 2008. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; The following
table summarizes the effect of derivative instruments on the consolidated
statements of income for the three and six months ended June&amp;#160;30,
2009 and 2008 (in millions): &lt;/div&gt; &lt;div style="margin-top: 6pt;
font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%"
align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family:
'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!--
Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="30%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="12%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=maindata --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="19%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=maindata --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=lead --&gt; &lt;td width="10%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Amount&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Amount&lt;br /&gt;
&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Recognized in&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Reclassified from&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Accumulated&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Accumulated&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Other&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Other&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 7pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Comprehensive&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Comprehensive&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 7pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Income on&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Income&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Income&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Income&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Amount
of&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Derivative&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Statement&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;into Income&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Statement&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Gain/(Loss)&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Gain/(Loss)&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Location&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Gain/(Loss)&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Location&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Recorded&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;&lt;i&gt;(Effective
Portion)&lt;/i&gt;&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;&lt;i&gt;(Effective
Portion)&lt;/i&gt;&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;&lt;i&gt;(Effective Portion)&lt;/i&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;&lt;i&gt;(Ineffective Portion)&lt;/i&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;&lt;i&gt;(Ineffective Portion)&lt;/i&gt;&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height: 3pt; font-size:
1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td align="left" valign="top"&gt; &lt;div
style="text-indent: -9pt; margin-left: 9pt"&gt; &lt;b&gt;For the Three Months
Ended&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; &lt;div style="text-indent:
-9pt; margin-left: 9pt"&gt; &lt;b&gt;June&amp;#160;30, 2009:&lt;/b&gt; &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td align="left" valign="top"&gt; &lt;div style="text-indent: -9pt; margin-left:
9pt"&gt; Foreign currency contracts &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="top"&gt; (31.7 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="top"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; Revenue &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt; (9.2 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td align="left" valign="top"&gt; Other income (expense)
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt;
1.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; &lt;div style="text-indent: -9pt; margin-left:
9pt"&gt; &lt;b&gt;June&amp;#160;30, 2008:&lt;/b&gt; &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
align="left" valign="top"&gt; &lt;div style="text-indent: -9pt; margin-left:
9pt"&gt; Foreign currency contracts &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="top"&gt; (14.9 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="top"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; Revenue &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt; (10.1
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td align="left" valign="top"&gt; Other
income (expense) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="top"&gt; (0.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="top"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Interest rate swap
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="top"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; Interest expense &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; Interest expense &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="top"&gt; (3.7 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; ) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="line-height: 9pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left" valign="top"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; &lt;b&gt;For the Six
Months Ended&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; &lt;div style="text-indent:
-9pt; margin-left: 9pt"&gt; &lt;b&gt;June&amp;#160;30, 2009:&lt;/b&gt; &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td align="left" valign="top"&gt; &lt;div style="text-indent: -9pt; margin-left:
9pt"&gt; Foreign currency contracts &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="top"&gt; (31.7 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="top"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; Revenue &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt; (12.3
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td align="left" valign="top"&gt; Other
income (expense) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="top"&gt; (0.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; &lt;div style="text-indent: -9pt; margin-left:
9pt"&gt; &lt;b&gt;June&amp;#160;30, 2008:&lt;/b&gt; &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
align="left" valign="top"&gt; &lt;div style="text-indent: -9pt; margin-left:
9pt"&gt; Foreign currency contracts &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="top"&gt; (14.9 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="top"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; Revenue &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt; (17.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td align="left" valign="top"&gt; Other
income (expense) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="top"&gt; (1.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="top"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Interest rate swap
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="top"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; Interest expense &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="top"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="top"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; Interest expense &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="top"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="top"&gt; (5.0 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; ) &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Other
Derivatives&lt;/font&gt;&lt;/i&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; During the quarter
ended June&amp;#160;30, 2009 we entered into several foreign currency forward
contracts to mitigate the foreign currency risk related to certain intercompany
transactions. We have not elected hedge accounting for these transactions.
As of June&amp;#160;30, 2009 the notional amount of these foreign currency
contracts was $80.0&amp;#160;million. The fair value of the foreign currency
contracts was insignificant. During the quarter, total gains of $1.4&amp;#160;million
were recognized as a component of other income (expense), net related to the
transactions. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;/div&gt; &lt;/body&gt; &lt;/html&gt; </biib:FinancialInstrumentsTextBlock>
<!-- End Block Tagged Note --> <!-- Begin Block Tagged Note --> <biib:PropertyPlantAndEquipmentsTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 7 - us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock--&gt;
&lt;div style="margin-left: 0%"&gt; &lt;table width="100%" border="0" cellpadding="0"
cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;tr&gt; &lt;td width="3%"&gt;&lt;/td&gt;
&lt;td width="97%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt;
&lt;b&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;7.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/b&gt; &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Property, plant and equipment are recorded
at historical cost, net of accumulated depreciation of $588.8&amp;#160;million
and $537.0&amp;#160;million as of June&amp;#160;30, 2009 and December&amp;#160;31,
2008, respectively. &lt;/div&gt; &lt;/div&gt; &lt;!-- END PAGE WIDTH --&gt;
&lt;!-- PAGEBREAK --&gt; &lt;div style="margin-left: 0%"&gt; &lt;!-- BEGIN
PAGE WIDTH --&gt; &lt;div style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt;
&lt;div align="center" style="margin-left: 0%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt; &lt;/font&gt;
&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; font-size: 1pt"&gt;
&lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div align="center" style="margin-left:
0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/i&gt; &lt;/b&gt; &lt;/div&gt;
&lt;div style="margin-top: 18pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;/div&gt; &lt;/body&gt; &lt;/html&gt; </biib:PropertyPlantAndEquipmentsTextBlock>
<!-- End Block Tagged Note --> <!-- Begin Block Tagged Note --> <biib:EarningsPerShareTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 9 - us-gaap:EarningsPerSharePolicyTextBlock--&gt; &lt;div style="margin-left:
0%"&gt; &lt;table width="100%" border="0" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;tr&gt; &lt;td width="3%"&gt;&lt;/td&gt; &lt;td width="97%"&gt;&lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;9.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Earnings per Share&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;/table&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Basic and diluted earnings per share are
calculated as follows (in millions): &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%"
align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family:
'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!--
Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="64%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;For the&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Three
Months&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Six Months&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Ended&lt;br /&gt;
&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Ended&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;June&amp;#160;30,&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;June&amp;#160;30,&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom"
align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="line-height: 3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Numerator: &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 10pt"&gt; Net income attributable to Biogen Idec Inc.&amp;#160;
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 142.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 206.6 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 386.8
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
369.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Adjustment for net income allocable to preferred
stock &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (0.2 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (0.3 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(0.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (0.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Net income used
in calculating basic and diluted earnings per share &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 142.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
206.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 386.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 369.1 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Denominator: &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Weighted average number of common shares outstanding
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 288.6 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 290.4
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 288.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 293.3 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Effect of dilutive securities: &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 20pt"&gt; Stock options and employee stock purchase plan &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 0.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 1.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 0.7 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
2.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 20pt"&gt; Time-vested restricted stock units &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 1.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1.2 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 20pt"&gt; Performance-vested restricted
stock units &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 20pt"&gt; Restricted stock awards &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 0.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Dilutive potential common shares &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1.8 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
3.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 3.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Shares used in calculating diluted earnings
per share &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 290.4 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
293.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 290.0 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 296.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left: 0%; margin-right:
0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; The following
amounts were not included in the calculation of net income per share because
their effects were anti-dilutive or the performance criteria had not been
met for the performance-vested restricted stock units (in millions): &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;table border="0" width="100%" align="center" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt; &lt;tr style="font-size:
1pt" valign="bottom"&gt; &lt;td width="65%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;For the&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Three
Months Ended&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Six Months Ended&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;June&amp;#160;30,&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;June&amp;#160;30,&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height: 3pt;
font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Numerator: &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 20pt"&gt; Net income allocable to preferred stock &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
0.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
0.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
0.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
0.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Denominator: &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 20pt"&gt; Stock options &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
7.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 4.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 7.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 5.2 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 20pt"&gt;
Time-vested restricted stock units &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1.1 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
0.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 0.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 20pt"&gt; Performance-vested restricted stock units &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt"&gt; Convertible preferred
stock &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 0.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 0.5 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
0.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 0.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size:
1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
30pt"&gt; Total &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 9.0 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
4.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 8.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 5.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
Effective January&amp;#160;1, 2009, we implemented FSP &lt;font style="white-space:
nowrap"&gt;EITF&amp;#160;03-6-1,&lt;/font&gt; &lt;i&gt;Determining Whether
Instruments Granted in Share-Based Payment Transactions Are Participating
Securities&lt;/i&gt;, or FSP &lt;font style="white-space: nowrap"&gt;EITF&amp;#160;03-6-1.&lt;/font&gt;
FSP &lt;font style="white-space: nowrap"&gt;EITF&amp;#160;03-6-1&lt;/font&gt;
addresses whether instruments granted in share-based payment transactions
are participating securities prior to vesting, and therefore need to be included
in the earnings allocation in computing earnings per share under the two-class
method as described in Statement of Financial Accounting Standards No.&amp;#160;128,
&lt;i&gt;Earnings per Share&lt;/i&gt;. Under the guidance of FSP &lt;font
style="white-space: nowrap"&gt;EITF&amp;#160;03-6-1,&lt;/font&gt; unvested
share-based payment awards that contain nonforfeitable rights to dividends
or dividend equivalents, whether paid or unpaid, are participating securities
and shall be included in the computation of earnings per share pursuant to
the two-class method. Our awards do not have nonforfeitable rights to dividends
or dividend equivalents and therefore the adoption of this FSP did not impact
our financial position or results of operations. &lt;/div&gt; &lt;div style="margin-top:
12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;/div&gt; &lt;/body&gt;
&lt;/html&gt; </biib:EarningsPerShareTextBlock> <!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note --> <biib:ShareBasedPaymentsTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 10 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock--&gt;
&lt;div style="margin-left: 0%"&gt; &lt;table width="100%" border="0" cellpadding="0"
cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;tr&gt; &lt;td width="5%"&gt;&lt;/td&gt;
&lt;td width="95%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt;
&lt;b&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;10.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Share-Based Payments&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;/table&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Our share-based compensation programs consist
of share-based awards which include stock options, time-vested restricted
stock units and performance-vested restricted stock units, as well as our
employee stock purchase plan. &lt;/div&gt; &lt;div style="margin-top: 12pt;
font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;Shared-based compensation expense&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; For the three and six months ended June&amp;#160;30,
2009 and 2008, share-based compensation expense recorded in accordance with
Statement of Financial Accounting Standards No.&amp;#160;123 (revised 2004),
&lt;i&gt;Share-Based Payments&lt;/i&gt;, or SFAS&amp;#160;123(R), reduced
our results of operations as follows (in millions, except per share amounts):
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;table border="0" width="100%" align="center" cellpadding="0"
cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt;
&lt;tr style="font-size: 1pt" valign="bottom"&gt; &lt;td width="45%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;For the&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Three
Months Ended&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Six Months Ended&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;June&amp;#160;30,&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;June&amp;#160;30,&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Effect on&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Effect on&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Net
Income&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Net Income&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:
3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Income before income
taxes &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (41.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (33.1 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; (78.9 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (67.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Tax effect &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 12.7 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
10.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 24.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 20.8 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 10pt"&gt; Net income attributable
to Biogen Idec, Inc.&amp;#160; &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (28.4 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (23.1
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (54.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (46.8
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double
#000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Share-based compensation expense and capitalized
share-based costs for the three and six months ended June&amp;#160;30, 2009
and 2008 were as follows (in millions): &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%"
align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family:
'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!--
Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="34%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="10" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;For the&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Three Months Ended June&amp;#160;30, 2009&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Three Months Ended June&amp;#160;30, 2008&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Stock&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Restricted Stock&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Stock&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Restricted
Stock&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Options &lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;and Restricted&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Options&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;and Restricted&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;&amp;#038; ESPP&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;Stock Units&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;Total&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;&amp;#038; ESPP&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Stock Units&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;Total&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="line-height: 3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -9pt;
margin-left: 9pt"&gt; Research and development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1.2
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
12.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
14.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
12.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
14.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Selling, general and
administrative &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 5.2 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
23.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 28.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 3.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 17.0 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
20.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div
style="text-indent: -9pt; margin-left: 9pt"&gt; Total &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 6.4
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
36.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
42.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
5.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
29.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
35.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left: 9pt"&gt;
Capitalized share-based payment costs &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (1.4
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (1.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-9pt; margin-left: 9pt"&gt; Share-based compensation expense &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 41.1
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 33.1
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div align="left"
style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt;
font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;/div&gt; &lt;div style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt;
&lt;/div&gt; &lt;!-- END PAGE WIDTH --&gt; &lt;!-- PAGEBREAK --&gt; &lt;div
style="margin-left: 0%"&gt; &lt;!-- BEGIN PAGE WIDTH --&gt; &lt;div style="margin-top:
0pt; font-size: 1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left:
0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times
New Roman', Times"&gt; &lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
0pt; font-size: 1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left:
0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times
New Roman', Times"&gt; &lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div align="center"
style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial,
Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font
style="font-family: 'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/i&gt;
&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;table border="0" width="100%" align="center" cellpadding="0"
cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;!-- Table Width Row BEGIN --&gt;
&lt;tr style="font-size: 1pt" valign="bottom"&gt; &lt;td width="34%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=01 type=maindata --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=06 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=lead --&gt; &lt;td width="8%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=07 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="10" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;For the&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Six Months Ended June&amp;#160;30, 2009&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="10" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Six Months Ended June&amp;#160;30, 2008&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Stock&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Restricted Stock&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Stock&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Restricted
Stock&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="font-size: 7pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Options&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;and Restricted&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Options&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;and Restricted&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
7pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;&amp;#038; ESPP&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;Stock Units&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;Total&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;&amp;#038; ESPP&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Stock Units&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;Total&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="line-height: 3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -9pt;
margin-left: 9pt"&gt; Research and development &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 3.4
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
27.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
30.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
3.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
28.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
31.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Selling, general and
administrative &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 9.8 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
41.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 51.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 7.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 32.3 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
39.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div
style="text-indent: -9pt; margin-left: 9pt"&gt; Total &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 13.2
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
68.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
82.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
11.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
60.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
71.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -9pt; margin-left: 9pt"&gt;
Capitalized share-based payment costs &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (3.1
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (3.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background:
#CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent:
-9pt; margin-left: 9pt"&gt; Share-based compensation expense &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 78.9
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 67.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div align="left"
style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt;
font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Stock Options&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
The fair values of our stock option grants are estimated as of the date of
grant using a Black-Scholes option valuation model. The estimated fair values
of the stock options, including the effect of estimated forfeitures, are then
expensed over the options&amp;#8217; vesting periods. &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
During the six months ended June&amp;#160;30, 2009, approximately 996,000
stock options were granted with a weighted average exercise price of $50.05
per share. Approximately 825,000 of these stock options were granted during
the first quarter of 2009, of which approximately 775,000 were granted in
connection with our annual awards made in February; the remainder of the stock
options granted during the six months ended June&amp;#160;30, 2009 were made
in conjunction with promotions or hiring of employees and grants made to members
of our Board of Directors. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; During the six months
ended June&amp;#160;30, 2008, approximately 1.3&amp;#160;million stock options
were granted with a weighted average exercise price of $60.70 per share. Approximately
1.2&amp;#160;million of these stock options were granted during the first
quarter of 2008, of which approximately 1.1&amp;#160;million were granted
in connection with our annual awards made in February; the remainder of the
stock options granted during the six months ended June&amp;#160;30, 2008 were
made in conjunction with the promotion or hiring of employees and grants made
to members of our Board of Directors. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Stock options
awarded as part of the annual award in each of February 2009 and 2008 were
granted with exercise prices of $49.65 per share and $60.56 per share, respectively,
except the grants to our Chief Executive Officer, which were granted with
exercise prices of $50.55 per share and $63.24 per share, respectively. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; In the three and six months ended June&amp;#160;30,
2009, we recognized $6.0&amp;#160;million and $11.2&amp;#160;million, respectively,
of share-based compensation expense related to stock options awarded as compared
to $4.7&amp;#160;million and $9.5&amp;#160;million, respectively, during the
prior year comparative periods. &lt;/div&gt; &lt;/div&gt; &lt;!-- END PAGE
WIDTH --&gt; &lt;!-- PAGEBREAK --&gt; &lt;div style="margin-left: 0%"&gt;
&lt;!-- BEGIN PAGE WIDTH --&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div align="center" style="margin-left:
0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/i&gt; &lt;/b&gt; &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; The fair values of the stock option grants awarded
for the six months ended June&amp;#160;30, 2009 and 2008 were estimated as
of the date of grant using a Black-Scholes option valuation model that uses
the following assumptions: &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%" align="center"
cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!-- Table
Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt; &lt;td
width="83%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata --&gt;
&lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Six Months&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Ended&lt;br /&gt;
&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;June&amp;#160;30,&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="line-height: 3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Expected dividend yield &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 0.0 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; % &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
0.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; %
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Expected stock price
volatility &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 39.3 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; % &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
34.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; %
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 10pt"&gt; Risk-free interest rate &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; %
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 2.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
% &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt"&gt; Expected option
life in years &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 4.7 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 5.1 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Weighted average per share grant date fair value &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 18.03
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
21.07 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div
style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family:
Arial, Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font
style="font-family: 'Times New Roman', Times"&gt;Time-Vested Restricted Stock
Units&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; The fair values
of our time-vested restricted stock units, or RSUs, are based on the market
value of our stock on the date of grant and are recognized over the applicable
service period, adjusted for the effect of estimated forfeitures. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; During the six months ended June&amp;#160;30, 2009,
approximately 2.4&amp;#160;million RSUs were granted with a weighted average
grant date fair value of $49.37 per share. Approximately 2.3&amp;#160;million
of these RSUs were granted during the first quarter of 2009, of which approximately
2.1&amp;#160;million of these RSUs were granted in connection with our annual
awards made in February; the remainder of the RSUs granted during the six
months ended June&amp;#160;30, 2009 were made in conjunction with promotions
or hiring of employees and grants made to members of our Board of Directors.
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; During the six months ended June&amp;#160;30,
2008, approximately 2.6&amp;#160;million RSUs were granted with a weighted
average grant date fair value of $60.60 per share. Approximately 2.5&amp;#160;million
of these RSUs were granted during the first quarter of 2008, of which approximately
2.4&amp;#160;million were granted in connection with our annual awards made
in February; the remainder of the RSUs granted during the six months ended
June&amp;#160;30, 2008 were made in conjunction with the promotion or hiring
of employees and grants made to members of our Board of Directors. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; RSUs awarded as part of the annual grant in each
of February 2009 and 2008 had grant date fair values of $49.65 per share and
$60.56 per share, respectively, except the grants to our Chief Executive Officer,
which had grant date fair values of $50.55 per share and $63.24 per share,
respectively. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; For the three and six months ended June&amp;#160;30,
2009, we recognized approximately $33.9&amp;#160;million and $65.4&amp;#160;million,
respectively, of share-based compensation expense related to RSU, as compared
to approximately $29.9&amp;#160;million and $59.1&amp;#160;million, respectively,
recognized in the prior year comparative periods. &lt;/div&gt; &lt;div style="margin-top:
12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;Performance-Vested Restricted Stock Units&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; We apply a graded vesting expense methodology
when accounting for our performance-vested restricted stock units, or PVRSUs,
in accordance with SFAS&amp;#160;123(R). For the three and six months ended
June&amp;#160;30, 2009, we recorded $2.2&amp;#160;million and $3.4&amp;#160;million,
respectively, of share-based compensation expense related to PVRSUs as compared
to $0.1&amp;#160;million and $0.7&amp;#160;million, respectively, for the
prior year comparative periods. &lt;/div&gt; &lt;div style="margin-top: 6pt;
font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; During the six
months ended June&amp;#160;30, 2009, approximately 318,000 PVRSUs were granted
with a weighted average grant date fair value of $49.48 per share. Approximately
307,000 of these PVRSUs were granted during the first quarter of 2009, of
which approximately 291,000 were in connection with our annual awards made
in February; the remainder of the PVRSUs granted during the six months ended
June&amp;#160;30, 2009 were made in conjunction with promotions or hiring
of employees. These PVRSUs are eligible to vest in full or in part and are
earned subject to the attainment of certain performance criteria established
at the beginning of the performance period; the performance period ends December&amp;#160;31,
2009. Once the earned number of performance-vested awards have been determined,
the earned PVRSUs will then vest in three equal increments on (1)&amp;#160;the
later of the first anniversary of the grant date or the date of results determination;
(2)&amp;#160;the second anniversary of the grant date; and (3)&amp;#160;the
third anniversary of the grant date. The vesting of these awards are also
subject to the respective employees&amp;#8217; continued employment. The fair
values of these PVRSUs are based on the market price of our stock on the date
of grant. Compensation expense associated with these PVRSUs is initially based
upon the number of shares expected to vest after assessing the probability
that certain performance criteria will be met and the associated targeted
payout level that is forecasted will be achieved, net of estimated forfeitures.
Cumulative adjustments are recorded quarterly to reflect subsequent changes
in the estimated outcome of performance-related conditions until the date
results are determined. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; During 2007, our Board
of Directors awarded a total of 120,000 PVRSUs to Dr.&amp;#160;Cecil Pickett,
our President, Research and Development. Vesting of these PVRSUs is subject
to certain performance criteria established at the beginning of each of four
performance periods, beginning January 1 on each of 2007, 2008, 2009 and 2010.
Up to 30,000 PVRSUs are eligible to vest each performance period and convert
into shares of our common stock subject to attainment of certain performance
criteria and Dr.&amp;#160;Pickett&amp;#8217;s continued employment through
the end of the respective performance period; the performance periods end
on December&amp;#160;31, 2007, December&amp;#160;31, 2008, December&amp;#160;31,
2009 and September&amp;#160;30, 2010. The fair values of the PVRSUs granted
to Dr.&amp;#160;Pickett are based on the market price of our stock on the
date of grant, adjusted quarterly for subsequent changes in the market price
of our stock. As of June&amp;#160;30, 2008, a total of 27,000&amp;#160;shares
were issued based upon the attainment of performance criteria set for 2007.
As of June&amp;#160;30, 2009, an additional 30,000&amp;#160;shares were issued
based on the attainment of performance criteria set for 2008. &lt;/div&gt;
&lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 2%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Employee
Stock Purchase Plan&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
The purchase price of common stock under the employee stock purchase plan,
or ESPP, is equal to 85% of the lower of (i)&amp;#160;the market value per
share of the common stock on the participant&amp;#8217;s entry date into an
offering period or (ii)&amp;#160;the market value per share of the common
stock on the Purchase Date. However, for each participant whose entry date
is other than the start date of the offering period, the amount shall in no
event be less than the market value per share of the common stock as of the
beginning of the related offering period. The fair value of the discounted
purchases made under the employee stock purchase plan are calculated using
the Black-Scholes model. The fair value of the look-back provision plus the
15% discount is recognized as compensation expense over the purchase period.
We apply a graded vesting approach since our ESPP provides for multiple purchase
periods and is, in substance, a series of linked awards. &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
During the three and six months ended June&amp;#160;30, 2009, a total of approximately
0.1&amp;#160;million and 0.3&amp;#160;million shares, respectively, were issued
under the ESPP as compared to a total of approximately 0.1&amp;#160;million
and 0.3&amp;#160;million shares, respectively, issued during the prior year
comparative periods. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; For the three and
six months ended June&amp;#160;30, 2009, we recognized approximately $0.4&amp;#160;million
and $2.0&amp;#160;million, respectively, of share-based compensation expense
in relation to the ESPP as compared to approximately $0.5&amp;#160;million
and $1.6&amp;#160;million, respectively, recognized in the prior year comparative
periods. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;/div&gt; &lt;/body&gt; &lt;/html&gt; </biib:ShareBasedPaymentsTextBlock>
<!-- End Block Tagged Note --> <!-- Begin Block Tagged Note --> <us-gaap:IncomeTaxDisclosureTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 11 - us-gaap:IncomeTaxDisclosureTextBlock--&gt; &lt;div style="margin-left:
0%"&gt; &lt;table width="100%" border="0" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;tr&gt; &lt;td width="5%"&gt;&lt;/td&gt; &lt;td width="95%"&gt;&lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;11.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Income Taxes&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Our effective tax rate was 39.0% and 28.7% for the
three and six months ended June&amp;#160;30, 2009, respectively, compared
to 28.9% and 31.0% for the prior year comparative periods. &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
The effective tax rate for the six months ended June&amp;#160;30, 2009 was
favorably impacted by changes in tax law that became effective during 2009
in certain state jurisdictions in which we operate. These changes required
us to establish assets for certain tax credits and adjust certain deferred
tax liabilities and reserves for uncertain tax positions, having a favorable
effect of 5.5%. This favorable effect was offset by the impact of the collaboration
and license agreement entered into with Acorda Therapeutics, Inc., or Acorda.
There is no income tax benefit associated with the upfront payment made to
Acorda, by a &lt;font style="white-space: nowrap"&gt;non-U.S.&amp;#160;affiliate,&lt;/font&gt;
which had a 7.5% and 2.3% unfavorable effect for the three and six months
ended June&amp;#160;30, 2009, respectively. Refer to Note&amp;#160;13, &lt;i&gt;Collaborations&lt;/i&gt;,
of this &lt;font style="white-space: nowrap"&gt;Form&amp;#160;10-Q&lt;/font&gt;
for additional information related to the Acorda transaction. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Our effective tax rate for the six months ended June&amp;#160;30,
2008 was favorably impacted by the restructuring of our operations in foreign
jurisdictions as well as other activities. Reconciliation between the U.S.&amp;#160;federal
statutory tax rate and our effective tax rate for the three and six months
ended June&amp;#160;30, 2009 and 2008 is as follows: &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table
border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;!-- Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="57%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="6%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;For the&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Three
Months&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Six Months&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Ended&lt;br /&gt;
&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Ended&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;June&amp;#160;30,&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;June&amp;#160;30,&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom"
align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="line-height: 3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Statutory rate &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
35.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; %
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 35.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
% &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 35.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
% &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 35.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
% &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; State taxes &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 4.1 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 1.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 2.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 10pt"&gt; Taxes on foreign earnings
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (2.7 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (11.2 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(4.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (10.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; ) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Credits and net operating loss utilization &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(1.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 0.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; (5.9 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (0.5 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Fair value adjustment &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 4.4 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
3.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 2.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 3.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; IPR&amp;#038;D &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 1.2 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
1.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Non-deductible items &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(2.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (0.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (1.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (0.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Other &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 0.7 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
0.1 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 0.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; &amp;#8212; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 10pt"&gt; Effective tax rate &lt;/div&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 39.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
% &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 28.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
% &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 28.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
% &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 31.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
% &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left: 0%; margin-right:
0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; On September&amp;#160;12,
2006, we received a Notice of Assessment from the Massachusetts Department
of Revenue for $38.9&amp;#160;million, including penalties and interest, with
respect to the 2002 tax year. Subsequently, we filed a petition with the Massachusetts
Appellate Tax Board, seeking among other items, abatements of corporate excise
tax for the 2001, 2002 and 2003 tax years. We believe that we have meritorious
defenses to the proposed adjustment and are vigorously opposing the assessment.
We believe that the assessment does not impact the level of liabilities for
income tax contingencies. However, there is a possibility that we may not
prevail in all of our assertions. If this is resolved unfavorably in the future,
it could have a material impact on our results of operations in the period
the resolution occurs. We are subject to examinations by the Massachusetts
Department of Revenue for additional tax years and, therefore, may be assessed
for a similar proposed adjustment to those additional tax years. Refer to
Note&amp;#160;14, &lt;i&gt;Litigation, &lt;/i&gt;of this &lt;font style="white-space:
nowrap"&gt;Form&amp;#160;10-Q&lt;/font&gt; for additional information. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; We file income tax returns in the United States federal
jurisdiction, and various states and foreign jurisdictions. With few exceptions,
we are no longer subject to U.S.&amp;#160;federal, state and local, or &lt;font
style="white-space: nowrap"&gt;non-U.S.&amp;#160;income&lt;/font&gt; tax examinations
by tax authorities for years before 2001. During the second quarter of 2007,
the Internal Revenue Service, or IRS, completed its examination of our consolidated
federal income tax returns for the fiscal years 2003 and 2004 and issued an
assessment. During the first quarter of 2009 the IRS completed an examination
of our consolidated federal income tax returns for fiscal years 2005 and 2006
and issued an assessment. Our level of liabilities for income tax contingencies
approximate those amounts for items agreed to with the IRS; we are appealing
several other items. If this is resolved unfavorably in the future, the outcome
could have an impact on our results of operations in the period the resolution
occurs. &lt;/div&gt; &lt;/div&gt; &lt;!-- END PAGE WIDTH --&gt; &lt;!-- PAGEBREAK
--&gt; &lt;div style="margin-left: 0%"&gt; &lt;!-- BEGIN PAGE WIDTH --&gt;
&lt;div style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt; &lt;div align="center"
style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial,
Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div
style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt; &lt;div align="center"
style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial,
Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div
align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt;
font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt;
&lt;i&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt; &lt;/font&gt;
&lt;/i&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 18pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;/div&gt; &lt;/body&gt; &lt;/html&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
<!-- End Block Tagged Note --> <!-- Begin Block Tagged Note --> <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 12 - us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock--&gt;
&lt;div style="margin-left: 0%"&gt; &lt;table width="100%" border="0" cellpadding="0"
cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;tr&gt; &lt;td width="5%"&gt;&lt;/td&gt;
&lt;td width="95%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt;
&lt;b&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;12.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Other Income (Expense), Net&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;/table&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Total other income (expense), net, consists
of the following (in millions): &lt;/div&gt; &lt;div style="margin-top: 6pt;
font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%"
align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family:
'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!--
Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="45%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;For the&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Three
Months&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Six Months&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Ended&lt;br /&gt;
&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Ended&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;June&amp;#160;30,&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;June&amp;#160;30,&lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom"
align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="line-height: 3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Interest income &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 12.1
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
15.3 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
26.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
38.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left:
10pt"&gt; Interest expense &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (9.3
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(13.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (19.2 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; ) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; (29.6 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="background: #CCEEFF"&gt; &lt;td align="left"
valign="bottom"&gt; &lt;div style="text-indent: -10pt; margin-left: 10pt"&gt;
Impairments of investments &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; (3.5
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; ) &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(5.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (9.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (14.6 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; ) &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-10pt; margin-left: 10pt"&gt; Other, net &lt;/div&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
15.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 0.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 23.4 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 5.1 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid
#000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 10pt"&gt; Total other income (expense),
net &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 14.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; (4.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
) &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
21.5 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
(0.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; )
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left: 0%; margin-right:
0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div style="margin-top:
12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;Impairment on Investments&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; During the three and six months ended June&amp;#160;30,
2009, we recognized impairment losses of $3.5&amp;#160;million and $6.0&amp;#160;million,
respectively on our strategic investments and non-marketable securities. In
addition, during the three and six months ended June&amp;#160;30, 2008, we
recognized $3.0&amp;#160;million and $9.4&amp;#160;million, respectively,
in charges for the impairment of strategic investments and non-marketable
securities that were determined to be &lt;font style="white-space: nowrap"&gt;other-than-temporary.&lt;/font&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; No impairment losses were recognized through
earnings related to available for sale securities during the three months
ended June&amp;#160;30, 2009. For the six months ended June&amp;#160;30, 2009,
we recognized $3.6&amp;#160;million in charges for the impairment of available
for sale securities primarily related to mortgage and asset backed securities
when we lacked the ability and intent to hold the securities to recovery.
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; For the three and six months ended June&amp;#160;30,
2008, we recognized $2.9&amp;#160;million and $5.2&amp;#160;million, respectively,
in charges for the other-than-temporary impairment of available for sale securities
primarily related to mortgage and asset backed securities. &lt;/div&gt; &lt;div
style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family:
Arial, Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font
style="font-family: 'Times New Roman', Times"&gt;Other, net&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; During the three and six months ended June&amp;#160;30,
2009, Other, net included net gains on foreign currency of $1.9&amp;#160;million
and $7.4&amp;#160;million, respectively, and reflected $7.5&amp;#160;million
and $11.9&amp;#160;million, respectively, in net realized gains on marketable
securities. Other, net for the three and six months ended June&amp;#160;30,
2009 also included a $2.8&amp;#160;million gain recognized on the sale of
two strategic equity investments. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Other, net for
the three and six months ended June&amp;#160;30, 2008 included gains on sales
of marketable securities of $0.6&amp;#160;million and $6.0&amp;#160;million,
respectively. Other, net for the six months ended June&amp;#160;30, 2008 also
included losses on foreign currency of $0.9&amp;#160;million and hedge ineffectiveness
of $1.2&amp;#160;million, offset by a VAT refund of $3.8&amp;#160;million.
&lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Noncontrolling Interest&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Prior year amounts related to noncontrolling interest
(minority interest), historically reflected as a component of other income
(expense), net, have been reclassified to conform to current year presentation
as required by SFAS&amp;#160;160. The adoption of SFAS&amp;#160;160 has resulted
in the reclassification of amounts previously reported as minority interest
totaling $2.0&amp;#160;million and $4.6&amp;#160;million, being shown separately
from net income in the accompanying consolidated statement of income for the
three and six months ended June&amp;#160;30, 2009, respectively, as compared
to $1.4&amp;#160;million and $4.2&amp;#160;million, respectively, in the prior
year comparative periods. This reclassification did not have a material impact
on our previously reported financial position or results of operations. Refer
to Note&amp;#160;1, &lt;i&gt;Business Overview, &lt;/i&gt;and Note&amp;#160;8,
&lt;i&gt;Equity, &lt;/i&gt;of this &lt;font style="white-space: nowrap"&gt;Form&amp;#160;10-Q&lt;/font&gt;
for additional information on the adoption of SFAS&amp;#160;160. &lt;/div&gt;
&lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;/div&gt; &lt;/body&gt; &lt;/html&gt; </us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
<!-- End Block Tagged Note --> <!-- Begin Block Tagged Note --> <us-gaap:CollaborativeArrangementDisclosureTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 13 - biib:CollaborationsTextBlock--&gt; &lt;div style="margin-left:
0%"&gt; &lt;table width="100%" border="0" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;tr&gt; &lt;td width="5%"&gt;&lt;/td&gt; &lt;td width="95%"&gt;&lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;13.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Collaborations&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; In connection with our business strategy, we have
entered into various collaboration agreements which provide us with rights
to develop, produce and market products using certain know-how, technology
and patent rights maintained by our collaborative partners. Terms of the various
collaboration agreements may require us to make milestone payments upon the
achievement of certain product research and development objectives and pay
royalties on future sales, if any, of commercial products resulting from the
collaboration. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; EITF &lt;font style="white-space: nowrap"&gt;No.&amp;#160;07-01,&lt;/font&gt;
&lt;i&gt;Accounting for Collaborative Arrangements, &lt;/i&gt;or &lt;font
style="white-space: nowrap"&gt;EITF&amp;#160;07-01,&lt;/font&gt; prescribes
that certain transactions between collaborators be recorded in the income
statement on either a gross or net basis, depending on the characteristics
of the collaboration relationship, and provides for enhanced disclosure of
collaborative relationships. In accordance with &lt;font style="white-space:
nowrap"&gt;EITF&amp;#160;07-01,&lt;/font&gt; we evaluate our collaborative
agreements for proper income statement classification based on the nature
of the underlying activity. If payments to and from our collaborative partners
are not within the scope of other authoritative accounting literature, the
income statement classification for the payments is based on a reasonable,
rational analogy to authoritative accounting literature that is applied in
a consistent manner. Amounts due from our collaborative partners related to
development activities are generally reflected as a reduction of research
and development expense because the performance of contract development services
is not central to our operations. For collaborations with commercialized products,
if we are the principal, as defined in EITF &lt;font style="white-space: nowrap"&gt;No.&amp;#160;99-19,&lt;/font&gt;
&lt;i&gt;Reporting Revenue as a Principal versus Net as an Agent, &lt;/i&gt;or
&lt;font style="white-space: nowrap"&gt;EITF&amp;#160;99-19,&lt;/font&gt;
we record revenue and the corresponding operating costs in their respective
line items within our statement of income. If we are not the principal, we
record operating costs as a reduction of revenue. &lt;font style="white-space:
nowrap"&gt;EITF&amp;#160;99-19&lt;/font&gt; describes the principal as the
party who is responsible for delivering the product or service to the customer,
has latitude to determine price, and has the risks and rewards of providing
product or service to the customer, including inventory and credit risk. The
adoption of &lt;font style="white-space: nowrap"&gt;EITF&amp;#160;07-01&lt;/font&gt;
did not impact our financial position or results of operations; however it
resulted in enhanced disclosures for our collaboration activities. &lt;/div&gt;
&lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 2%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Genentech&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; We collaborate with Genentech, Inc., or
Genentech, wholly-owned subsidiary of Roche Holdings, Inc., on the development
and commercialization of RITUXAN. We also have rights to collaborate with
Genentech on the development and commercialization of (1)&amp;#160;anti-CD20
products that Genentech acquires or develops, which we refer to as New Anti-CD20
Products, and (2)&amp;#160;anti-CD20 products that Genentech licenses from
a third party, which we refer to as Third Party Anti-CD20 Products. Currently,
there is only one New Anti-CD20 Product, ocrelizumab, and only one Third Party
Anti-CD20 Product, GA101. Our collaboration rights for New Anti-CD20 Products
are limited to the United States and our collaboration rights for Third Party
Anti-CD20 Products are dependent upon Genentech&amp;#8217;s underlying license
rights. A joint development committee, or JDC, composed of three members from
each company must unanimously approve a development plan for each specific
indication of certain pharmaceutical products, and Genentech has responsibility
for implementation of JDC approved development plans in accordance with the
provisions of our collaboration agreement. In the event that we undergo a
change in control, as defined in the collaboration agreement, Genentech has
the right to present an offer to buy the rights to RITUXAN, and we must either
accept Genentech&amp;#8217;s offer or purchase Genentech&amp;#8217;s rights
to RITUXAN on the same terms as its offer. If Genentech presents such an offer,
then they will be deemed concurrently to have exercised a right, in exchange
for a royalty on net sales in the United States of any anti-CD20 product acquired
or developed by Genentech or any anti-CD20 product that Genentech licenses
from a third party that is developed under the agreement, to purchase our
interest in each such product. Our collaboration with Genentech was created
through a contractual arrangement and not through a joint venture or other
legal entity. &lt;/div&gt; &lt;/div&gt; &lt;!-- END PAGE WIDTH --&gt; &lt;!--
PAGEBREAK --&gt; &lt;div style="margin-left: 0%"&gt; &lt;!-- BEGIN PAGE WIDTH
--&gt; &lt;div style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt; &lt;div
align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt;
font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt;
&lt;font style="font-family: 'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt;
&lt;div align="center" style="margin-left: 0%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt; &lt;/font&gt;
&lt;/b&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font style="font-family: 'Times New Roman',
Times"&gt; &lt;/font&gt; &lt;/i&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; While Genentech
is responsible for the worldwide manufacturing of RITUXAN, development and
commercialization rights and responsibilities under this collaboration are
divided as follows: &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 2%;
margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000;
background: #FFFFFF"&gt; &lt;i&gt;&lt;font style="font-family: 'Times New
Roman', Times"&gt;United States&lt;/font&gt;&lt;/i&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
We share with Genentech co-exclusive rights to develop, commercialize and
market RITUXAN and New Anti-CD20 Products in the United States. Although we
contribute to the marketing and continued development of RITUXAN, we have
a limited sales force dedicated to RITUXAN and limited development activity.
Genentech is primarily responsible for the commercialization of RITUXAN in
the United States. Its responsibilities include selling and marketing, customer
service, order entry, distribution, shipping and billing, and other administrative
support. Genentech also incurs the majority of continuing development costs
for RITUXAN. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Canada&lt;/font&gt;&lt;/i&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; We and Genentech have assigned our rights
to develop, commercialize and market RITUXAN, in Canada to F. Hoffman-La&amp;#160;Roche
Ltd., or Roche. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Outside
the United States and Canada&lt;/font&gt;&lt;/i&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; We have granted
Genentech exclusive rights to develop, commercialize and market RITUXAN outside
the United States and Canada. Under the terms of separate sublicense agreements
between Genentech and Roche, development and commercialization of RITUXAN
outside the United States and Canada is the responsibility of Roche, except
in Japan where RITUXAN is co-marketed by Zenyaku Kogyo Co. Ltd., or Zenyaku,
and Chugai Pharmaceutical Co. Ltd, or Chugai, an affiliate of Roche. We do
not have any direct contractual arrangements with Roche, Zenyaku or Chugai
for such development or commercialization. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Revenues from
unconsolidated joint business consists of (1)&amp;#160;our share of pretax
co-promotion profits in the United States (2)&amp;#160;reimbursement of selling
and development expenses in the United States; and (3)&amp;#160;revenue on
sales of RITUXAN outside the United States, which consist of our share of
pretax co-promotion profits in Canada and royalty revenue on sales of RITUXAN
outside the United States and Canada by Roche, Zenyaku and Chugai. Pre-tax
co-promotion profits are calculated and paid to us by Genentech in the United
States and by Roche in Canada. Pre-tax co-promotion profits consist of Unites
States and Canadian sales of RITUXAN to third-party customers net of discounts
and allowances less the cost to manufacture RITUXAN, third-party royalty expenses,
distribution, selling, and marketing expenses, and joint development expenses
incurred by Genentech, Roche and us. We record our royalty and co-promotion
profits revenue on sales of RITUXAN outside the United States on a cash basis.
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Revenues from unconsolidated joint business
consist of the following (in millions): &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%"
align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family:
'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!--
Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=04 type=hang1 --&gt; &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=gutter --&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=lead --&gt; &lt;td width="4%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=05 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;For the Three&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;For the Six&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Months
Ended&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap" align="center"
valign="bottom"&gt; &lt;b&gt;Months Ended&lt;br /&gt; &lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt"
valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6"
nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid
#000000"&gt; &lt;b&gt;June&amp;#160;30,&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="6" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;June&amp;#160;30,&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2009&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom" style="border-bottom: 1px solid #000000"&gt;
&lt;b&gt;2009&lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;2008&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height: 3pt;
font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"
style="background: #CCEEFF"&gt; &lt;td align="left" valign="bottom"&gt; &lt;div
style="text-indent: -10pt; margin-left: 10pt"&gt; Co-promotion profits in
the United States &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 198.5 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 177.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
378.0 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 335.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 10pt"&gt; Reimbursement of selling and development expenses in
the United&amp;#160;States &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 16.7
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 15.9 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 31.7 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 28.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom" style="background: #CCEEFF"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 10pt"&gt; Revenue on sales of RITUXAN outside the United States
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 60.4 &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 85.2
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 144.7 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 161.7 &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px
solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid
#000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
1px solid #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 1px solid #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td align="left" valign="bottom"&gt; &lt;div style="text-indent: -10pt;
margin-left: 20pt"&gt; Total unconsolidated joint business &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
$ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt; 275.6
&lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
278.8 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td nowrap="nowrap" align="right"
valign="bottom"&gt; 554.4 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; $ &lt;/td&gt; &lt;td
nowrap="nowrap" align="right" valign="bottom"&gt; 526.0 &lt;/td&gt; &lt;td
nowrap="nowrap" align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr valign="bottom" style="font-size: 1pt"&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td
style="border-top: 3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top:
3px double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px
double #000000"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt;
&amp;#160; &lt;/td&gt; &lt;td style="border-top: 3px double #000000"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;/div&gt; &lt;/div&gt; &lt;!-- END PAGE WIDTH --&gt; &lt;!-- PAGEBREAK
--&gt; &lt;div style="margin-left: 0%"&gt; &lt;!-- BEGIN PAGE WIDTH --&gt;
&lt;div style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt; &lt;div align="center"
style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial,
Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div
style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt; &lt;div align="center"
style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial,
Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div
align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt;
font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt;
&lt;i&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt; &lt;/font&gt;
&lt;/i&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; Under the collaboration
agreement, our current pretax co-promotion profit-sharing formula, which resets
annually, is stated within the table below. In 2009 and 2008, the 40% threshold
was met during the first quarter. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table border="0" width="100%"
align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family:
'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;!--
Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="87%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02
type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=02 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Biogen Idec&amp;#8217;s&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom"
align="center"&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2"
nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;Share of&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Co-promotion&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="border-bottom:
1px solid #000000; width: 1%; padding-bottom: 1px"&gt; &lt;b&gt;Co-promotion
Operating Profits&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"
style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Profits&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height: 3pt;
font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="text-indent:
-9pt; margin-left: 9pt"&gt; First $50&amp;#160;million &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
30 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; % &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td align="left" valign="bottom"&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt"&gt; Greater than $50&amp;#160;million
&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 40 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; % &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div align="left"
style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt;
font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Our agreement with Genentech provides that
the successful development and commercialization of the first New Anti-CD20
Product will decrease our percentage of co-promotion profits of the collaboration
and that we will participate in Third Party Anti-CD20 Products on similar
financial terms as for ocrelizumab. Specifically, for each calendar year or
portion thereof following the approval date of the first New Anti-CD20 Product,
the pretax co-promotion profit-sharing formula for RITUXAN and New Anti-CD20
Products sold by us and Genentech will change as follows. &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table
border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size:
9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
&lt;!-- Table Width Row BEGIN --&gt; &lt;tr style="font-size: 1pt" valign="bottom"&gt;
&lt;td width="43%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=01 type=maindata
--&gt; &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=gutter
--&gt; &lt;td width="41%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=02 type=maindata
--&gt; &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=03 type=gutter
--&gt; &lt;td width="1%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!-- colindex=03
type=lead --&gt; &lt;td width="9%" align="right"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=body --&gt; &lt;td width="1%" align="left"&gt;&amp;#160;&lt;/td&gt;&lt;!--
colindex=03 type=hang1 --&gt; &lt;/tr&gt; &lt;!-- Table Width Row END --&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Biogen Idec&amp;#8217;s&lt;br
/&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &amp;#160;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap"
align="center" valign="bottom"&gt; &lt;b&gt;Share of&lt;br /&gt; &lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size:
8pt" valign="bottom" align="center"&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; &lt;b&gt;First New
Anti-CD20 Product U.S.&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center" valign="bottom"&gt;
&lt;b&gt;Co-promotion&lt;br /&gt; &lt;/b&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-size: 8pt" valign="bottom" align="center"&gt;
&lt;td nowrap="nowrap" align="left" valign="bottom"&gt; &lt;div style="border-bottom:
1px solid #000000; width: 1%; padding-bottom: 1px"&gt; &lt;b&gt;Co-promotion
Operating Profits&lt;/b&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom" style="border-bottom:
1px solid #000000"&gt; &lt;b&gt;Gross Product Sales&lt;/b&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td colspan="2" nowrap="nowrap" align="center"
valign="bottom" style="border-bottom: 1px solid #000000"&gt; &lt;b&gt;Profits&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:
3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="bottom"&gt; &lt;td align="left" valign="top"&gt; &lt;div style="text-indent:
-9pt; margin-left: 9pt"&gt; First $50 million(1) &lt;/div&gt; &lt;/td&gt;
&lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="center" valign="bottom"&gt;
Not Applicable &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="left" valign="bottom"&gt; &amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap"
align="right" valign="bottom"&gt; 30 &lt;/td&gt; &lt;td nowrap="nowrap" align="left"
valign="bottom"&gt; % &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td
align="left" valign="top"&gt; &lt;div style="text-indent: -9pt; margin-left:
9pt"&gt; Greater than $50 million &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td align="center" valign="bottom"&gt; Until such sales exceed
$150&amp;#160;million&lt;br /&gt; in any calendar year(2) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
38 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; % &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; Or &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td align="center" valign="bottom"&gt; After such sales exceed
$150&amp;#160;million in&lt;br /&gt; any calendar year until such sales&lt;br
/&gt; exceed $350&amp;#160;million in any calendar year(3) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
35 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; % &lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap" align="left"
valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160; &lt;/td&gt;
&lt;td nowrap="nowrap" align="center" valign="bottom"&gt; Or &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;/tr&gt; &lt;tr valign="bottom"&gt; &lt;td nowrap="nowrap"
align="left" valign="top"&gt; &amp;#160; &lt;/td&gt; &lt;td&gt; &amp;#160;
&lt;/td&gt; &lt;td align="center" valign="bottom"&gt; After such sales exceed
$350&amp;#160;million in&lt;br /&gt; any calendar year(4) &lt;/td&gt; &lt;td&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt;
&amp;#160; &lt;/td&gt; &lt;td nowrap="nowrap" align="right" valign="bottom"&gt;
30 &lt;/td&gt; &lt;td nowrap="nowrap" align="left" valign="bottom"&gt; % &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div align="left" style="margin-left: 0%; margin-right:
0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div style="font-size:
1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"&gt;
&lt;/div&gt;&lt;!-- callerid=999 iwidth=456 length=60 --&gt; &lt;div style="margin-top:
3pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table width="100%" border="0"
cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;tr&gt; &lt;td
width="2%"&gt;&lt;/td&gt; &lt;td width="1%"&gt;&lt;/td&gt; &lt;td width="97%"&gt;&lt;/td&gt;
&lt;/tr&gt; &lt;tr&gt; &lt;td align="right" valign="top"&gt; (1) &lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;td valign="bottom"&gt; not applicable in the calendar
year the first New Anti-CD20 Product is approved if $50&amp;#160;million in
co-promotion operating profits has already been achieved in such calendar
year through sales of RITUXAN.&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:
3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt;
&lt;td align="right" valign="top"&gt; (2) &lt;/td&gt; &lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; if we are recording our share of RITUXAN co-promotion
profits at 40%, upon the approval date of the first New Anti-CD20 Product,
our share of co-promotion profits for RITUXAN and the New Anti-CD20 Product
will be immediately reduced to 38% following the approval date of the first
New Anti-CD20 Product until the $150&amp;#160;million in first New Anti-CD20
Product sales level is achieved.&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:
3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt;
&lt;td align="right" valign="top"&gt; (3) &lt;/td&gt; &lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt; if $150&amp;#160;million in first New Anti-CD20
Product sales is achieved in the same calendar year the first New Anti-CD20
Product receives approval, then the 35% co-promotion profit-sharing rate will
not be effective until January 1 of the following calendar year. Once the
$150&amp;#160;million in first New Anti-CD20 Product sales level is achieved
then our share of co-promotion profits for the balance of the year and all
subsequent years (after the first $50&amp;#160;million in co-promotion operating
profits in such years) will be 35% until the $350&amp;#160;million in first
New Anti-CD20 Product sales level is achieved.&lt;/td&gt; &lt;/tr&gt; &lt;tr
style="line-height: 3pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt; &lt;tr&gt; &lt;td align="right" valign="top"&gt; (4) &lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;td valign="bottom"&gt; if $350&amp;#160;million
in first New Anti-CD20 Product sales is achieved in the same calendar year
that $150&amp;#160;million in new product sales is achieved, then the 30%
co-promotion profit-sharing rate will not be effective until January 1 of
the following calendar year (or January 1 of the second following calendar
year if the first New Anti-CD20 Product receives approval and, in the same
calendar year, the $150&amp;#160;million and $350&amp;#160;million in first
New Anti-CD20 Product sales levels are achieved). Once the $350&amp;#160;million
in first New Anti-CD20 Product sales level is achieved then our share of co-promotion
profits for the balance of the year and all subsequent years will be 30%.&lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;!-- END PAGE WIDTH --&gt; &lt;!--
PAGEBREAK --&gt; &lt;div style="margin-left: 0%"&gt; &lt;!-- BEGIN PAGE WIDTH
--&gt; &lt;div style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt; &lt;div
align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt;
font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt;
&lt;font style="font-family: 'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 0pt; font-size: 1pt"&gt; &lt;/div&gt;
&lt;div align="center" style="margin-left: 0%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt; &lt;/font&gt;
&lt;/b&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font style="font-family: 'Times New Roman',
Times"&gt; &lt;/font&gt; &lt;/i&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Currently, we
record our share of the expenses incurred by the collaboration for the development
of New Anti-CD20 Products in research and development expense in our consolidated
statement of income. After a New Anti-CD20 Product is approved, we will record
our share of the development expenses related to that product as a reduction
of our share of pretax co-promotion profits in revenues from unconsolidated
joint business. We incurred $17.7&amp;#160;million and $32.7&amp;#160;million
in development expense related to New Anti-CD20 products for the three and
six months ended June&amp;#160;30, 2009, respectively, as compared to $10.6&amp;#160;million
and $22.5&amp;#160;million, respectively, during the prior year comparative
periods. Reimbursement to Genentech for our share of these costs occurs through
the net amount of co-promotion profits in the United States remitted to us.
&lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Elan&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; We have a collaboration
agreement with Elan to collaborate in the development, manufacture and commercialization
of TYSABRI. Under the terms of the agreement, we manufacture TYSABRI and collaborate
with Elan on the product&amp;#8217;s marketing, commercial distribution and
on-going development activities. The collaboration with Elan is designed to
effect an equal sharing of profits and losses generated by the activities
of the collaboration between Elan and us. Under the agreement, however, once
sales of TYSABRI exceeded specific thresholds, Elan was required to make milestone
payments to us in order to continue sharing equally in the collaboration&amp;#8217;s
results. As of June&amp;#160;30, 2009, Elan has paid to us milestone payments
of $75.0&amp;#160;million in the third quarter of 2008 and $50.0&amp;#160;million
in the first quarter of 2009. We have recorded these amounts as deferred revenue
upon receipt and are recognizing the entire $125.0&amp;#160;million as product
revenue in our consolidated statement of income over the term of the collaboration
agreement based on a units of revenue method whereby the revenue recognized
is based on the ratio of units shipped in the current period over the total
units expected to be shipped over the remaining term of the collaboration.
No additional milestone payments are required under the agreement to maintain
the current profit sharing split. Our collaboration agreement with Elan provides
Elan or us with the option to buy the rights to TYSABRI in the event that
the other company was to undergo a change of control (as defined in the collaboration
agreement). &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; In the United States, Elan and we co-market
TYSABRI, with us primarily responsible for marketing TYSABRI for MS, and Elan
primarily responsible for marketing TYSABRI for Crohn&amp;#8217;s disease.
We sell TYSABRI to Elan who sells the product to third party distributors.
Our sales price to Elan in the United States is set prior to the beginning
of each quarterly period to effect an approximate equal sharing of the gross
margin between Elan and us. We recognize revenue for sales in the Unites States
of TYSABRI upon Elan&amp;#8217;s shipment of the product to the third party
distributors. We incur manufacturing and distribution costs, research and
development expenses, commercial expenses, and general and administrative
expenses. We record these expenses to their respective line items within our
statement of income when they are incurred. Research and development and sales
and marketing expenses are shared with Elan and the reimbursement of these
expenses is recorded as reductions of the respective expense categories. During
the three and six months ended June&amp;#160;30, 2009, we recorded $3.7&amp;#160;million
and $11.2&amp;#160;million, respectively, as reductions of research and development
expense for reimbursements from Elan as compared to $8.0&amp;#160;million
and $13.3&amp;#160;million, respectively, of research and development expense
recorded for reimbursement from Elan during the prior year comparative periods.
In addition, for the three and six months ended June&amp;#160;30, 2009, we
recorded $8.5&amp;#160;million and $17.5&amp;#160;million, respectively, as
reductions of selling, general and administrative expense for reimbursements
from Elan as compared to $7.0&amp;#160;million and $16.0&amp;#160;million,
respectively, in the prior year comparative periods. &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
Outside the United States, or rest of world, we are responsible for distributing
TYSABRI to customers and are primarily responsible for all operating activities.
Generally, we recognize revenue for sales of TYSABRI in the rest of world
at the time of product delivery to our customers. Payments are made to Elan
for their share of the rest of world net operating profits to effect an equal
sharing of collaboration operating profit. These payments include the reimbursement
of our portion of third-party royalties that Elan pays on behalf of the collaboration
relating to rest of world sales. These amounts are reflected in the collaboration
profit sharing line in our consolidated statement of income. For the three
and six months ended June&amp;#160;30, 2009, $49.1&amp;#160;million and $91.9&amp;#160;million,
respectively, was reflected in the collaboration profit sharing line for our
collaboration with Elan, as compared to $33.4&amp;#160;million and $54.8&amp;#160;million,
respectively, for the prior year comparative periods. As rest of world sales
of TYSABRI increase, our collaboration profit sharing expense is expected
to increase. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Acorda&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; On June&amp;#160;30,
2009, we entered into a collaboration and license agreement with Acorda to
develop and commercialize products containing Fampridine-SR in markets outside
the United States. Fampridine-SR is an oral sustained-release compound, which
is being developed to improve walking ability in people with MS. The transaction
represents a sublicensing of an existing license agreement between Acorda
and Elan. The parties have also entered into a related supply agreement. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Under the terms of the agreement, we will commercialize
Fampridine-SR and any aminopyridine products developed in our territory and
will also have responsibility for regulatory activities and future clinical
development of Fampridine-SR in those markets. As of June&amp;#160;30, 2009,
we have recorded within accounts payable a liability for the $110.0&amp;#160;million
upfront payment due to Acorda. We may also incur up to an additional $400.0&amp;#160;million
of milestone payments based upon the successful achievement of regulatory
and commercial sales milestones. We will also make tiered royalty payments
to Acorda on sales outside of the United States. The consideration that we
pay for products will reflect all amounts due from Acorda to Elan for sales
in markets outside the United States, including royalties owed. The parties
can also carry out future joint development activities under a cost-sharing
arrangement. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Elan will continue to manufacture commercial
supply of Fampridine-SR, based upon its existing supply agreement with Acorda.
Under the existing agreements with Elan, Acorda will pay Elan seven percent
of the upfront and milestone payments that Acorda receives from us. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; The $110.0&amp;#160;million upfront payment was recorded
as research and development expense as the asset has not received regulatory
approval. For the three and six months ended June&amp;#160;30, 2009, we did
not record any additional research and development expense related to the
Acorda transaction in our consolidated statement of income. &lt;/div&gt; &lt;div
style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family:
Arial, Helvetica; color: #000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font
style="font-family: 'Times New Roman', Times"&gt;Neurimmune&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; We have a collaboration agreement with Neurimmune
SubOne AG, or Neurimmune, a subsidiary of Neurimmune Therapeutics AG, for
the development and commercialization of antibodies for the treatment of Alzheimer&amp;#8217;s
disease. The royalty term under the agreement for sales in each country will
be no less than 12&amp;#160;years from the first commercial sale of product
using such compound in such country. Neurimmune will conduct research to identify
potential therapeutic antibodies and we will be responsible for the development,
manufacturing and commercialization of all products. Under the terms of the
agreement, we may pay up to an additional $360.0&amp;#160;million in milestone
payments, as well as a royalty on sales of any resulting commercial products.
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; We have determined that we are the primary
beneficiary of Neurimmune under FIN&amp;#160;46(R). As such, we consolidate
the results of Neurimmune. The assets and liabilities of Neurimmune are not
significant as it is a research and development organization. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; We incurred research and development expense of $2.5&amp;#160;million
and $7.5&amp;#160;million for the three and six months ended June&amp;#160;30,
2009, respectively, related to milestone payments. We incurred $8.0&amp;#160;million
of research and development expense related to milestone payments during the
six months ended June&amp;#160;30, 2008. No milestone payments were made during
the three months ended June&amp;#160;30, 2008. We reimburse Neurimmune for
all research and development costs incurred in support of the collaboration.
For the three and six months ended June&amp;#160;30, 2009, the collaboration
incurred $1.9&amp;#160;million and $3.7&amp;#160;million of expenses, respectively,
which were reflected in research and development expense in our statement
of income as compared to $2.0&amp;#160;million and $3.2&amp;#160;million of
research and development expense recognized for the three and six months ended
June&amp;#160;30, 2008, respectively. &lt;/div&gt; &lt;/div&gt; &lt;!-- END
PAGE WIDTH --&gt; &lt;!-- PAGEBREAK --&gt; &lt;div style="margin-left: 0%"&gt;
&lt;!-- BEGIN PAGE WIDTH --&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; font-size:
1pt"&gt; &lt;/div&gt; &lt;div align="center" style="margin-left: 0%; margin-right:
0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt; &lt;font style="font-family: 'Times New Roman', Times"&gt;
&lt;/font&gt; &lt;/b&gt; &lt;/div&gt; &lt;div align="center" style="margin-left:
0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt; &lt;i&gt; &lt;font style="font-family:
'Times New Roman', Times"&gt; &lt;/font&gt; &lt;/i&gt; &lt;/b&gt; &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Since inception of the collaboration excluding an
upfront payment of $2.0&amp;#160;million and milestone payments of $18.0&amp;#160;million,
we have spent an additional $10.0&amp;#160;million to develop the lead compound.
We may incur up to an additional $280.0&amp;#160;million to develop the lead
compound. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Cardiokine&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
We have a collaboration agreement with Cardiokine Biopharma LLC, or Cardiokine,
a subsidiary of Cardiokine Inc., for the joint development of Lixivaptan,
an oral compound for the potential treatment of hyponatremia in patients with
congestive heart failure. The royalty term under the agreement for sales in
each country will be no less than 10&amp;#160;years from the first commercial
sale of a Lixivaptan product in such country. If successful, we will be responsible
for certain development activities, manufacturing and global commercialization
of Lixivaptan, and Cardiokine has an option for limited co-promotion in the
United States. Under the terms of the agreement, excluding the $20.0&amp;#160;million
milestone payment incurred in July&amp;#160;2009, referred to below, we may
pay up to an additional $150.0&amp;#160;million in development milestone payments
as well as royalties on commercial sales. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; We have determined
that we are the primary beneficiary of Cardiokine under FIN&amp;#160;46(R).
As such, we consolidate the results of Cardiokine. The assets and liabilities
of Cardiokine are not significant as it is a research and development organization.
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; We reimburse Cardiokine for 90% of research
and development costs in support of the collaboration. For the three and six
months ended June&amp;#160;30, 2009, the collaboration incurred $17.5&amp;#160;million
and $31.2&amp;#160;million, respectively, which was reflected in research
and development expense in our consolidated statement of income as compared
to $13.5&amp;#160;million and $22.2&amp;#160;million, respectively, recognized
during the prior year comparative periods. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; For the three
and six months ended June&amp;#160;30, 2009, we have allocated $1.7&amp;#160;million
and $3.1&amp;#160;million, respectively, to net income attributable to noncontrolling
interest, net of tax, for the amount of research and development expense retained
by the noncontrolling interest holders. For the comparable periods in 2008,
we have allocated $1.3&amp;#160;million and $2.2&amp;#160;million, respectively,
to net income attributable to noncontrolling interest, net of tax, for the
amount of research and development expense retained by the noncontrolling
interest holders. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; In July 2009, Cardiokine
achieved a significant development milestone and triggered a $20.0&amp;#160;million
payment from us. As the triggering event for the payment occurred after June&amp;#160;30,
2009, the obligation is not reflected within our consolidated balance sheet
as of June&amp;#160;30, 2009. Such obligations are recorded when the milestone
has been achieved due to the uncertainty surrounding triggering events. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Since inception of the agreement excluding an upfront
payment of $50.0&amp;#160;million, we have incurred $91.2&amp;#160;million
to develop Lixivaptan. We may incur up to an additional $465.0&amp;#160;million
to develop Lixivaptan for all indications under development. &lt;/div&gt;
&lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 2%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Biovitrum&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; We have a collaboration agreement with Biovitrum
AB, or Biovitrum, to jointly develop and commercialize Factor VIII and Factor
IX for the treatment of hemophilia. Under the agreement, development and commercialization
costs and profits are shared equally. We have commercial rights to North America
and Biovitrum has commercial rights to Europe. All other territories are to
be managed by a third party with us and Biovitrum sharing equally in the operating
results. Under the agreement, Biovitrum may pay us up to an additional $19.5&amp;#160;million
in milestone payments. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; For the three and
six months ended June&amp;#160;30, 2009, the Factor VIII and Factor IX programs
collectively incurred expenses totaling $13.5&amp;#160;million and $26.4&amp;#160;million,
respectively, as compared to $8.8&amp;#160;million and $18.5&amp;#160;million,
respectively, incurred during the prior year comparative periods. Amounts
due from Biovitrum have been recorded as a reduction of research and development
expense. As such, we reflected $6.8&amp;#160;million and $13.2&amp;#160;million,
respectively, in research and development expense in our consolidated statement
of income for the three and six months ended June&amp;#160;30, 2009 and $4.4&amp;#160;million
and $9.3&amp;#160;million, respectively, for the three and six months ended
June&amp;#160;30, 2008. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; Since inception of
the agreement, we have incurred $41.4&amp;#160;million to develop Factor VIII
and Factor IX for the treatment of hemophilia. We may incur up to an additional
$55.0&amp;#160;million to develop Factor VIII and Factor IX for this indication.
&lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Mondo&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; We have a collaboration
agreement with MondoGen, or Mondo, a subsidiary of MondoBiotech AG, to develop
and commercialize Aviptadil, a clinical compound for the treatment of pulmonary
arterial hypertension, or PAH. Under the agreement, we are responsible for
manufacturing, development, and commercialization of the compound and could
incur up to $30.0&amp;#160;million in milestones payments for successful development
and commercialization of the program in the United States and Europe, as well
as royalty payments on commercial sales. In February 2009, the parties revised
the agreement to clarify that our development funding obligation should not
exceed $13.3&amp;#160;million, inclusive of all amounts incurred during 2009
and the three months ended December&amp;#160;31, 2008, if we decide not to
pursue the collaboration beyond 2009. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; We have determined
that we are the primary beneficiary of Mondo under FIN&amp;#160;46(R). As
such, we consolidate the results of Mondo. The assets and liabilities of Mondo
are not significant as it is a research and development organization. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; For the three and six months ended June&amp;#160;30,
2009, the collaboration incurred $3.8&amp;#160;million and $6.9&amp;#160;million,
respectively, which was reflected in research and development expense in our
consolidated statement of income as compared to $3.5&amp;#160;million and
$9.0&amp;#160;million, respectively, in the prior year comparative periods.
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Since inception of the agreement excluding
an upfront payment of $7.5&amp;#160;million, we have incurred $36.8&amp;#160;million
to develop Aviptadil in PAH. &lt;/div&gt; &lt;div style="margin-top: 12pt;
font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;UCB&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Since inception of our collaboration agreement with
UCB, S.A., or UCB, we have incurred a total of $94.4&amp;#160;million in research
and development expenses for the development and commercialization of an oral
alpha4 integrin, or VLA-4, antagonist for the treatment of relapsing remitting
MS. The total research and development expenses incurred are inclusive of
an upfront payment made in the amount of $30.0&amp;#160;million. In June 2009,
UCB and we announced the discontinuation of the Phase&amp;#160;II clinical
trial for this collaboration&amp;#8217;s only product candidate due to the
absence of clinically relevant efficacy. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; For the three
and six months ended June&amp;#160;30, 2009, the collaboration incurred $13.5&amp;#160;million
and $22.3&amp;#160;million, respectively. Our share of the collaboration expenses
were $8.5&amp;#160;million and $14.3&amp;#160;million, respectively, which
is reflected in research and development expense in our consolidated statement
of income. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; For the three and six months ended June&amp;#160;30,
2008, the collaboration incurred $9.5&amp;#160;million and $16.5&amp;#160;million,
respectively. Our share of the collaboration expenses were $5.7&amp;#160;million
and $10.3&amp;#160;million, respectively, which is reflected in research and
development expense in our consolidated statement of income. &lt;/div&gt;
&lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 2%; margin-right: 0%; font-size:
10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"&gt;
&lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;Facet
Biotech&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; We have a collaboration
agreement with Facet Biotech, or Facet, aimed at advancing the development
and commercialization of daclizumab in MS and volociximab in solid tumors.
Daclizumab is a humanized monoclonal antibody that binds to the IL-2 receptor
on activated T cells. Volociximab is an anti-angiogenic chimeric antibody
directed against alpha5 beta1 integrin, or VLA5. Under the agreement, development,
and commercialization costs and profits are shared equally. We may incur up
to an additional $650.0&amp;#160;million of payments upon achievement of development
and commercial milestones. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; For the three and
six months ended June&amp;#160;30, 2009, the collaboration incurred $9.5&amp;#160;million
and $17.7&amp;#160;million, respectively. As a result, we reflected $4.8&amp;#160;million
and $8.9&amp;#160;million, respectively, in research and development expense
in our consolidated statement of income. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; For the three
and six months ended June&amp;#160;30, 2008, the collaboration incurred $20.3&amp;#160;million
and $39.6&amp;#160;million, respectively. As a result, we reflected $10.1&amp;#160;million
and $19.8&amp;#160;million, respectively, in research and development expense
in our consolidated statement of income. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; Since inception
of the collaboration excluding an upfront payment of $40.0&amp;#160;million
and milestone payments of $10.0&amp;#160;million, we have incurred $49.0&amp;#160;million
and $60.6&amp;#160;million to develop daclizumab and volociximab, respectively.
We may incur up to an additional $250.0&amp;#160;million and $170.0&amp;#160;million,
respectively, to develop daclizumab and volociximab in these indications.
&lt;/div&gt; &lt;div style="margin-top: 12pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 2%; margin-right: 0%;
font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Vernalis&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; We have a collaboration
agreement with Vernalis plc, or Vernalis, aimed at advancing the development
and commercialization of an adenosine A2a receptor antagonist for treatment
of Parkinson&amp;#8217;s disease. Under the agreement, we received exclusive
worldwide rights to develop and commercialize the compound. We are responsible
for funding all development costs and may incur up to an additional $85.0&amp;#160;million
of milestone payments upon achievement of certain objectives, as well as royalties
on commercial sales. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; For the three and
six months ended June&amp;#160;30, 2009, we incurred $2.8&amp;#160;million
and $7.1&amp;#160;million, respectively, which is reflected in research and
development expense in our consolidated statement of income, as compared to
$5.3&amp;#160;million and $8.8&amp;#160;million, respectively, in the prior
year comparative periods. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; Since inception of
the collaboration excluding an upfront payment of $10.0&amp;#160;million and
a milestone payment of $3.0&amp;#160;million, we have incurred $61.8&amp;#160;million
to develop a compound for treatment of Parkinson&amp;#8217;s disease. We may
incur up to an additional $160.0&amp;#160;million to develop the compound
in this indication. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;/div&gt; &lt;/body&gt; &lt;/html&gt; </us-gaap:CollaborativeArrangementDisclosureTextBlock>
<!-- End Block Tagged Note --> <!-- Begin Block Tagged Note --> <biib:LitigationTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 14 - biib:LitigationTextBlock--&gt; &lt;div style="margin-left:
0%"&gt; &lt;table width="100%" border="0" cellpadding="0" cellspacing="0"
style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background:
#FFFFFF"&gt; &lt;tr&gt; &lt;td width="5%"&gt;&lt;/td&gt; &lt;td width="95%"&gt;&lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;14.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Litigation&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; Along with several other major pharmaceutical and
biotechnology companies, Biogen, Inc. (now Biogen Idec MA, Inc., one of our
wholly-owned subsidiaries) or, in some cases, Biogen Idec Inc., was named
as a defendant in lawsuits filed by the City of New York and numerous Counties
of the State of New York. All of the cases&amp;#160;&amp;#8212; except for
cases filed by the County of Erie, County of Oswego and County of Schenectady,
or the Three County Actions&amp;#160;&amp;#8212; are the subject of a Consolidated
Complaint, first filed on June&amp;#160;15, 2005 in the U.S.&amp;#160;District
Court for the District of Massachusetts in Multi-District Litigation No.&amp;#160;1456,
or the MDL proceedings. The complaints allege that the defendants (i)&amp;#160;fraudulently
reported the Average Wholesale Price for certain drugs for which Medicaid
provides reimbursement, or the Covered Drugs; (ii)&amp;#160;marketed and promoted
the sale of Covered Drugs to providers based on the providers&amp;#8217; ability
to collect inflated payments from the government and Medicaid beneficiaries
that exceeded payments possible for competing drugs; (iii)&amp;#160;provided
financing incentives to providers to over-prescribe Covered Drugs or to prescribe
Covered Drugs in place of competing drugs; and (iv)&amp;#160;overcharged Medicaid
for illegally inflated Covered Drugs reimbursements. Among other things, the
complaints allege violations of New York state law and advance common law
claims for unfair trade practices, fraud, and unjust enrichment. In addition,
the amended Consolidated Complaint alleges that the defendants failed to accurately
report the &amp;#8220;best price&amp;#8221; on the Covered Drugs to the Secretary
of Health and Human Services pursuant to rebate agreements, and excluded from
their reporting certain discounts and other rebates that would have reduced
the &amp;#8220;best price.&amp;#8221; With respect to the MDL proceedings,
some of the plaintiffs&amp;#8217; claims were dismissed, and the parties,
including Biogen Idec, began a mediation of the outstanding claims on July&amp;#160;1,
2008. We have not formed an opinion that an unfavorable outcome is either
&amp;#8220;probable&amp;#8221; or &amp;#8220;remote&amp;#8221; in any of these
cases, and do not express an opinion at this time as to their likely outcome
or as to the magnitude or range of any potential loss. We believe that we
have good and valid defenses to each of these complaints and are vigorously
defending against them. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; On June&amp;#160;17,
2006, Biogen Idec filed a Demand for Arbitration against Genentech, Inc. with
the American Arbitration Association, or the AAA, which Demand was amended
on December&amp;#160;5, 2006 and on January&amp;#160;29, 2008. In the Demand,
Biogen Idec alleged that Genentech breached the parties&amp;#8217; Amended
and Restated Collaboration Agreement dated June&amp;#160;19, 2003, or the
Collaboration Agreement, by failing to honor Biogen Idec&amp;#8217;s right
to participate in strategic decisions affecting the parties&amp;#8217; joint
development of certain pharmaceutical products, including humanized anti-CD20
antibodies. Genentech filed an Answering Statement in response to Biogen Idec&amp;#8217;s
Demand in which Genentech denied that it had breached the Collaboration Agreement
and alleged that Biogen Idec had breached the Collaboration Agreement. In
its Answering Statement, filed in 2006, Genentech also asserted for the first
time that the November 2003 transaction in which Idec Pharmaceuticals acquired
Biogen and became Biogen Idec was a change of control under the Collaboration
Agreement. On June&amp;#160;15, 2009, the arbitration panel issued its final
decision (the &amp;#8220;Award&amp;#8221;). The panel ruled that a Joint Development
Committee (JDC) composed of three members from each company must unanimously
approve a separate development plan for each specific indication (disease).
The panel also ruled that, absent unanimous approval of the JDC, which may
not be unreasonably withheld, Genentech may not proceed with further development
of 2H7v16 in neuromyelitis optica, 2H7v16 in relapsing-remitting multiple
sclerosis, or 2H7v114 for oncology. The panel ruled that Genentech may continue
clinical trials of 2H7 for lupus and Phase&amp;#160;III clinical trials of
2H7 for rheumatoid arthritis. The panel also confirmed Genentech&amp;#8217;s
undisputed responsibility for implementation of JDC approved development plans
in accordance with the provisions of the Collaboration Agreement. The panel
rejected Genentech&amp;#8217;s assertion of the &amp;#8220;Change of Control&amp;#8221;
provision under the Collaboration Agreement. The panel did not award damages
to either party. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; On September&amp;#160;12, 2006, the Massachusetts
Department of Revenue, or the DOR, issued a notice of assessment against Biogen
Idec MA, Inc. for $38.9&amp;#160;million of corporate excise tax with respect
to the 2002 tax year, which includes associated interest and penalties. On
December&amp;#160;6, 2006, we filed an abatement application with the DOR,
seeking abatements for 2001, 2002 and 2003 tax years. The abatement application
was denied on July&amp;#160;24, 2007. On July&amp;#160;25, 2007, we filed
a petition with the Massachusetts Appellate Tax Board, seeking, among other
items, abatements of corporate excise tax for 2001, 2002 and 2003 tax years
and adjustments in certain credits and credit carryforwards for 2001, 2002
and 2003 tax years. Issues before the Board include the computation of Biogen
Idec MA&amp;#8217;s sales factor for 2001, 2002 and 2003 tax years, computation
of Biogen Idec MA&amp;#8217;s research credits for those same years, and the
availability of deductions for certain expenses and partnership flow-through
items. We anticipate that the trial will take place in 2010. We intend to
contest this matter vigorously. &lt;/div&gt; &lt;div style="margin-top: 6pt;
font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; On October&amp;#160;4,
2004, Genentech, Inc. received a subpoena from the U.S.&amp;#160;Department
of Justice requesting documents related to the promotion of RITUXAN. We market
RITUXAN in the United States in collaboration with Genentech. Genentech has
disclosed that it is cooperating with the associated investigation, and that
it has been advised the investigation is civil in nature. We are cooperating
with the U.S.&amp;#160;Department of Justice in its investigation of Genentech.
The potential outcome of this matter and its impact on us cannot be determined
at this time. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; In January 2008, the European Commission,
or the EC, began an industry-wide antitrust inquiry into competitive conditions
within the pharmaceutical sector. As part of the inquiry, the EC requested
information from approximately 100&amp;#160;companies, including Biogen Idec.
The EC published its final report on the inquiry in July 2009 in which it
found delay in the market entry of generic drugs and a decline in drug innovation.
The report did not contain any findings regarding, or reference to, Biogen
Idec. The potential impact on us of the EC&amp;#8217;s final report cannot
be determined at this time. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; On October&amp;#160;27,
2008, Sanofi-Aventis Deutschland GmbH, or Sanofi, filed suit against Genentech
and Biogen Idec in federal court in Texas (E.D. Tex.), which we refer to as
the Texas Action claiming that Rituxan and certain other Genentech products
infringe U.S.&amp;#160;Patents 5,849,522, or the &amp;#8217;522 patent, and
6,218,140, or the &amp;#8217;140 patent. Sanofi seeks preliminary and permanent
injunctions, compensatory and exemplary damages, and other relief. On October&amp;#160;27,
2008, Genentech and Biogen Idec filed a complaint against Sanofi, Sanofi-Aventis
U.S.&amp;#160;LLC, and Sanofi-Aventis U.S.&amp;#160;Inc. in federal court
in California (N.D. Cal.), which we refer to as the California Action seeking
a declaratory judgment that Rituxan and other Genentech products do not infringe
the &amp;#8217;522 patent or the &amp;#8217;140 patent, and a declaratory
judgment that those patents are invalid. The parties are currently litigating
whether the Texas Action should be transferred to the court in the California
Action. In addition, on October&amp;#160;24, 2008, Hoechst GmbH filed with
the ICC International Court of Arbitration (Paris) a request for arbitration
against Genentech, relating to a terminated agreement between Hoechst&amp;#8217;s
predecessor and Genentech that pertained to the above-referenced patents and
related patents outside the U.S.&amp;#160;Hoechst is seeking payment of royalties
on sales of Genentech products, damages for breach of contract, and other
relief. We have not formed an opinion that an unfavorable outcome is either
&amp;#8220;probable&amp;#8221; or &amp;#8220;remote,&amp;#8221; and do not
express an opinion at this time as to the likely outcome of the matters or
as to the magnitude or range of any potential loss. We believe that we have
good and valid defenses and intend vigorously to defend against the allegations
against us. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; In addition, we are involved in product
liability claims and other legal proceedings generally incidental to our normal
business activities. While the outcome of any of these proceedings cannot
be accurately predicted, we do not believe the ultimate resolution of any
of these existing matters would have a material adverse effect on our business
or financial conditions. &lt;/div&gt; &lt;div style="margin-top: 12pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;/div&gt; &lt;/body&gt; &lt;/html&gt; </biib:LitigationTextBlock>
<!-- End Block Tagged Note --> <!-- Begin Block Tagged Note --> <us-gaap:SegmentReportingDisclosureTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 15 - us-gaap:SegmentReportingDisclosureTextBlock--&gt; &lt;div
style="margin-left: 0%"&gt; &lt;table width="100%" border="0" cellpadding="0"
cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;tr&gt; &lt;td width="5%"&gt;&lt;/td&gt;
&lt;td width="95%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt;
&lt;b&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;15.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;Segment Information&lt;/font&gt;&lt;/b&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;/table&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; We operate in one business segment, which
is the business of development, manufacturing and commercialization of novel
therapeutics for human health care and therefore, our chief operating &lt;font
style="white-space: nowrap"&gt;decision-maker&lt;/font&gt; manages the operation
of the Company as a single operating segment. &lt;/div&gt; &lt;div style="margin-top:
12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;/div&gt; &lt;/body&gt;
&lt;/html&gt; </us-gaap:SegmentReportingDisclosureTextBlock> <!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note --> <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD
XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
--&gt; &lt;html&gt; &lt;head&gt;&lt;/head&gt; &lt;body&gt; &lt;!-- Begin Block
Tagged Note 16 - us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock--&gt;
&lt;div style="margin-left: 0%"&gt; &lt;table width="100%" border="0" cellpadding="0"
cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;tr&gt; &lt;td width="5%"&gt;&lt;/td&gt;
&lt;td width="95%"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr valign="top"&gt; &lt;td&gt;
&lt;b&gt;&lt;font style="font-family: 'Times New Roman', Times"&gt;16.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt;
&lt;/td&gt; &lt;td&gt; &lt;b&gt;&lt;font style="font-family: 'Times New Roman',
Times"&gt;New Accounting Pronouncements&lt;/font&gt;&lt;/b&gt; &lt;/td&gt;
&lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; Effective January&amp;#160;1, 2009, we implemented
Statement of Financial Accounting Standards No.&amp;#160;141(R), &lt;i&gt;Business
Combination,&lt;/i&gt; or SFAS&amp;#160;141(R). This standard requires an
acquiring company to measure all assets acquired and liabilities assumed,
including contingent considerations and all contractual contingencies, at
fair value as of the acquisition date. In addition, an acquiring company is
required to capitalize IPR&amp;#038;D and either amortize it over the life
of the product, or write it off if the project is abandoned or impaired. The
adoption of this standard did not have a material impact on our financial
position or results of operations as SFAS&amp;#160;141(R) is applicable to
acquisitions completed after January&amp;#160;1, 2009 and we did not complete
any business combination transactions during the first six months of 2009.
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; SFAS&amp;#160;141(R) also amended Statement
of Financial Accounting Standards No.&amp;#160;109, &lt;i&gt;Accounting for
Income Taxes&lt;/i&gt;, or SFAS&amp;#160;109, and FASB Interpretation No.&amp;#160;48,
&lt;i&gt;Accounting for Uncertainty in Income Taxes&lt;/i&gt;, or FIN&amp;#160;48.
Previously, SFAS&amp;#160;109 and FIN&amp;#160;48, generally required post-acquisition
adjustments related to business combination deferred tax asset valuation allowances
and liabilities for uncertain tax positions to be recorded as an increase
or decrease to goodwill. SFAS&amp;#160;141(R) does not permit this accounting
and, generally, requires any such changes to be recorded in current period
income tax expense. Thus, all changes to valuation allowances and liabilities
for uncertain tax positions established in acquisition accounting, whether
the business combination was accounted for under SFAS&amp;#160;141 or SFAS&amp;#160;141(R),
will be recognized in current period income tax expense. &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
On April&amp;#160;1, 2009, the FASB Board issued FSP FAS&amp;#160;141(R)-1,
&lt;i&gt;Accounting for Assets Acquired and Liabilities Assumed in a Business
Combination That Arise from Contingencies, &lt;/i&gt;or FSP FAS&amp;#160;141(R)-1.
FSP FAS&amp;#160;141(R)-1 amends and clarifies SFAS&amp;#160;141(R), to address
application issues regarding the initial recognition and measurement, subsequent
measurement and accounting, and disclosure of assets and liabilities arising
from contingencies in a business combination. Due to the fact that SFAS&amp;#160;141(R)
is applicable to acquisitions completed after January&amp;#160;1, 2009 and
we did not have any business combinations in the first six months of 2009,
the adoption of FSP FAS&amp;#160;141(R)-1 did not impact our financial position
or results of operations. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size:
1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left: 0%;
margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New
Roman', Times; color: #000000; background: #FFFFFF"&gt; In April 2009, the
Securities and Exchange Commission, or SEC, issued Staff Accounting Bulletin
No. 111 which aligns SEC regulations to the newly issued accounting standards
(FSP FAS 115-1 and FAS 124-2) on accounting for other-than-temporary impairments
for marketable debt securities. Specifically, it amends Topic 5.M to exclude
debt securities from its scope. This bulletin did not impact our financial
position or results of operations; however, we conduct periodic reviews to
evaluate our investments for the other-than-temporary impairments in accordance
with FSP FAS&amp;#160;115-1. &lt;/div&gt; &lt;div style="margin-top: 6pt;
font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; In June 2009,
the SEC issued Staff Accounting Bulletin&amp;#160;No.&amp;#160;112, which
updates the SEC&amp;#8217;s rules and regulations to be consistent with the
accounting principles and standards established in SFAS&amp;#160;141(R) and
SFAS&amp;#160;160. This bulletin did not impact our financial position or
results of operations; however, the adoption of SFAS&amp;#160;160 resulted
in the reclassification of certain prior period amounts to conform to the
current financial statement presentation. &lt;/div&gt; &lt;div style="margin-top:
12pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color:
#000000; background: #FFFFFF"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="font-family:
'Times New Roman', Times"&gt;Recently Issued Accounting Standards&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;
&lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; On June&amp;#160;3, 2009, the FASB approved
the &lt;i&gt;FASB Accounting Standards Codification&lt;/i&gt;, or the Codification,
as the single source of authoritative nongovernmental Generally Accepted Accounting
Principles, or GAAP, in the United States. The Codification will be effective
for interim and annual periods ending after September&amp;#160;15, 2009, which
means July&amp;#160;1, 2009 for Biogen Idec. Upon the effective date, the
Codification will be the single source of authoritative accounting principles
to be applied by all nongovernmental U.S.&amp;#160;entities. All other accounting
literature not included in the Codification will be nonauthoritative. We do
not expect the adoption of the Codification to have an impact on our financial
position or results of operations. &lt;/div&gt; &lt;div style="margin-top:
6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div align="left" style="margin-left:
0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; In June 2009,
the FASB issued the following new accounting standards: &lt;/div&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;table
width="100%" border="0" cellpadding="0" cellspacing="0"&gt; &lt;tr&gt; &lt;td
width="4%"&gt;&lt;/td&gt; &lt;td width="2%"&gt;&lt;/td&gt; &lt;td width="94%"&gt;&lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="top" style="font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt; &amp;#8226;&amp;#160; &lt;/td&gt; &lt;td align="left"&gt; SFAS&amp;#160;No.&amp;#160;166,
&lt;i&gt;Accounting for Transfers of Financial Assets, an amendment of FASB
Statement No.&amp;#160;140&lt;/i&gt;, or SFAS&amp;#160;166; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="line-height: 6pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt; &lt;tr valign="top" style="font-size: 10pt; font-family: 'Times
New Roman', Times; color: #000000; background: #FFFFFF"&gt; &lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt; &amp;#8226;&amp;#160; &lt;/td&gt; &lt;td align="left"&gt; SFAS&amp;#160;No.&amp;#160;167,
&lt;i&gt;Amendments to FASB Interpretation No.&amp;#160;46(R), &lt;/i&gt;or
SFAS&amp;#160;167;&amp;#160;and &lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:
6pt; font-size: 1pt"&gt; &lt;td&gt;&amp;#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr
valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times;
color: #000000; background: #FFFFFF"&gt; &lt;td&gt;&amp;#160;&lt;/td&gt; &lt;td&gt;
&amp;#8226;&amp;#160; &lt;/td&gt; &lt;td align="left"&gt; SFAS&amp;#160;No.&amp;#160;168,
&lt;i&gt;The FASB Accounting Standards Codification and the Hierarchy of Generally
Accepted Accounting Principles, a replacement of FASB Statement No.&amp;#160;162,
or SFAS&amp;#160;168&lt;/i&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div
style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt; &lt;div
align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size:
10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"&gt;
SFAS&amp;#160;166 prescribes the information that a reporting entity must
provide in its financial reports about a transfer of financial assets; the
effects of a transfer on its financial position, financial performance, and
cash flows; and a transferor&amp;#8217;s continuing involvement in transferred
financial assets. Specifically, among other aspects, SFAS&amp;#160;166 amends
Statement of Financial Standard No.&amp;#160;140, &lt;i&gt;Accounting for
Transfers and Servicing of Financial Assets and Extinguishments of Liabilities&lt;/i&gt;,
or SFAS&amp;#160;140, by removing the concept of a qualifying special-purpose
entity from SFAS&amp;#160;140 and removes the exception from applying FIN&amp;#160;46(R)
to variable interest entities that are qualifying special-purpose entities.
It also modifies the financial-components approach used in SFAS&amp;#160;140.
SFAS&amp;#160;166 is effective for transfer of financial assets occurring
on or after January&amp;#160;1, 2010. We have not determined the effect that
the adoption of SFAS&amp;#160;166 will have on our financial position or results
of operations but the effect will generally be limited to future transactions.
Historically, we have not had any material transfer of financial assets. &lt;/div&gt;
&lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160; &lt;/div&gt;
&lt;div align="left" style="margin-left: 0%; margin-right: 0%; text-indent:
4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000;
background: #FFFFFF"&gt; SFAS&amp;#160;167 amends FASB Interpretation No.&amp;#160;46,
&lt;i&gt;Consolidation of Variable Interest Entities (revised December 2003)&amp;#160;&amp;#8212;
an interpretation of ARB No.&amp;#160;51&lt;/i&gt;, or FIN&amp;#160;46(R),
to require an enterprise to determine whether it&amp;#8217;s variable interest
or interests give it a controlling financial interest in a variable interest
entity. The primary beneficiary of a variable interest entity is the enterprise
that has both (1)&amp;#160;the power to direct the activities of a variable
interest entity that most significantly impact the entity&amp;#8217;s economic
performance and (2)&amp;#160;the obligation to absorb losses of the entity
that could potentially be significant to the variable interest entity or the
right to receive benefits from the entity that could potentially be significant
to the variable interest entity. SFAS&amp;#160;167 also amends FIN&amp;#160;46(R)
to require ongoing reassessments of whether an enterprise is the primary beneficiary
of a variable interest entity. SFAS&amp;#160;167 is effective for all variable
interest entities and relationships with variable interest entities existing
as of January&amp;#160;1, 2010. We have not determined the effect that the
adoption of SFAS&amp;#160;167 will have on our financial position or results
of operations. &lt;/div&gt; &lt;div style="margin-top: 6pt; font-size: 1pt"&gt;&amp;#160;
&lt;/div&gt; &lt;div align="left" style="margin-left: 0%; margin-right: 0%;
text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color:
#000000; background: #FFFFFF"&gt; SFAS&amp;#160;168 replaces SFAS&amp;#160;No.&amp;#160;162&lt;i&gt;,
The Hierarchy of Generally Accepted Accounting Principles, &lt;/i&gt;to establish
the &lt;i&gt;FASB Accounting Standards Codification &lt;/i&gt;as the source
of authoritative accounting principles recognized by the FASB to be applied
by nongovernmental entities in preparation of financial statements in conformity
with generally accepted accounting principles in the United States. SFAS&amp;#160;168
is effective for interim and annual periods ending after September&amp;#160;15,
2009. We do not expect the adoption of this standard to have an impact on
our financial position or results of operations. &lt;/div&gt; &lt;/div&gt;
&lt;!-- END PAGE WIDTH --&gt; &lt;/body&gt; &lt;/html&gt; </us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
<!-- End Block Tagged Note --> <biib:CollaborationProfitSharing
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">54835000</biib:CollaborationProfitSharing>
<biib:CollaborationProfitSharing contextRef="ThreeMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">33429000</biib:CollaborationProfitSharing> <biib:CollaborationProfitSharing
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">91911000</biib:CollaborationProfitSharing>
<biib:CollaborationProfitSharing contextRef="ThreeMonthsEnded_30Jun2009"
unitRef="USD" decimals="-3">49138000</biib:CollaborationProfitSharing> <biib:CollateralPayableOnLoanedSecurities
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-3">29991000</biib:CollateralPayableOnLoanedSecurities>
<biib:CollateralPayableOnLoanedSecurities
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">0</biib:CollateralPayableOnLoanedSecurities>
<biib:CollateralReceivedForLoanedSecurities
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-3">29991000</biib:CollateralReceivedForLoanedSecurities>
<biib:CollateralReceivedForLoanedSecurities
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">0</biib:CollateralReceivedForLoanedSecurities>
<biib:CollateralReceivedUnderSecuritiesLending
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">61253000</biib:CollateralReceivedUnderSecuritiesLending>
<biib:CollateralReceivedUnderSecuritiesLending
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">29991000</biib:CollateralReceivedUnderSecuritiesLending>
<biib:DueFromUnconsolidatedJointBusiness
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-3">206925000</biib:DueFromUnconsolidatedJointBusiness>
<biib:DueFromUnconsolidatedJointBusiness
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">198206000</biib:DueFromUnconsolidatedJointBusiness>
<biib:IncreaseDecreaseInDueFromUnconsolidatedJointBusiness
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-17535000</biib:IncreaseDecreaseInDueFromUnconsolidatedJointBusiness>
<biib:IncreaseDecreaseInDueFromUnconsolidatedJointBusiness
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">8719000</biib:IncreaseDecreaseInDueFromUnconsolidatedJointBusiness>
<biib:LoanedSecurities contextRef="BalanceAsOf_31Dec2008" unitRef="USD"
decimals="-3">29446000</biib:LoanedSecurities> <biib:LoanedSecurities
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">0</biib:LoanedSecurities>
<biib:NetIncomeLossAttributableToNoncontrollingInterest
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">4155000</biib:NetIncomeLossAttributableToNoncontrollingInterest>
<biib:NetIncomeLossAttributableToNoncontrollingInterest
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">1445000</biib:NetIncomeLossAttributableToNoncontrollingInterest>
<biib:NetIncomeLossAttributableToNoncontrollingInterest
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">4632000</biib:NetIncomeLossAttributableToNoncontrollingInterest>
<biib:NetIncomeLossAttributableToNoncontrollingInterest
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">2040000</biib:NetIncomeLossAttributableToNoncontrollingInterest>
<biib:NoncontrollingInterest contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">27869000</biib:NoncontrollingInterest> <biib:NoncontrollingInterest
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">33167000</biib:NoncontrollingInterest>
<biib:ObligationUnderSecuritiesLending
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-61253000</biib:ObligationUnderSecuritiesLending>
<biib:ObligationUnderSecuritiesLending
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-29991000</biib:ObligationUnderSecuritiesLending>
<biib:ProceedsFromSaleOfStrategicEquityInvestment
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">15000</biib:ProceedsFromSaleOfStrategicEquityInvestment>
<biib:ProceedsFromSaleOfStrategicEquityInvestment
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">5565000</biib:ProceedsFromSaleOfStrategicEquityInvestment>
<biib:ProfitLoss contextRef="SixMonthsEnded_30Jun2008" unitRef="USD"
decimals="-3">373880000</biib:ProfitLoss> <biib:ProfitLoss
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">208073000</biib:ProfitLoss>
<biib:ProfitLoss contextRef="January-01-2009_June-30-2009" unitRef="USD"
decimals="-3">391464000</biib:ProfitLoss> <biib:ProfitLoss
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">144885000</biib:ProfitLoss>
<biib:TotalShareholdersEquityBeforeNoncontrollingInterest
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-3">5806083000</biib:TotalShareholdersEquityBeforeNoncontrollingInterest>
<biib:TotalShareholdersEquityBeforeNoncontrollingInterest
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">6212538000</biib:TotalShareholdersEquityBeforeNoncontrollingInterest>
<biib:UnconsolidatedJointBusiness contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">526045000</biib:UnconsolidatedJointBusiness> <biib:UnconsolidatedJointBusiness
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">278822000</biib:UnconsolidatedJointBusiness>
<biib:UnconsolidatedJointBusiness
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">554388000</biib:UnconsolidatedJointBusiness>
<biib:UnconsolidatedJointBusiness contextRef="ThreeMonthsEnded_30Jun2009"
unitRef="USD" decimals="-3">275570000</biib:UnconsolidatedJointBusiness> <dei:AmendmentDescription
contextRef="January-01-2009_June-30-2009">N/A</dei:AmendmentDescription> <dei:AmendmentFlag
contextRef="January-01-2009_June-30-2009">false</dei:AmendmentFlag> <dei:CurrentFiscalYearEndDate
contextRef="January-01-2009_June-30-2009">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentPeriodEndDate contextRef="January-01-2009_June-30-2009">2009-06-30</dei:DocumentPeriodEndDate>
<dei:DocumentType contextRef="January-01-2009_June-30-2009">10-Q</dei:DocumentType>
<dei:EntityCentralIndexKey contextRef="January-01-2009_June-30-2009">0000875045</dei:EntityCentralIndexKey>
<dei:EntityCommonStockSharesOutstanding
contextRef="BalanceAsOf_13Jul2009" unitRef="Shares" decimals="INF">288855922</dei:EntityCommonStockSharesOutstanding>
<dei:EntityCurrentReportingStatus
contextRef="January-01-2009_June-30-2009">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityFilerCategory contextRef="January-01-2009_June-30-2009">Large Accelerated
Filer</dei:EntityFilerCategory> <dei:EntityPublicFloat
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="INF">13005469098.8</dei:EntityPublicFloat>
<dei:EntityRegistrantName contextRef="January-01-2009_June-30-2009">Biogen
Idec Inc.</dei:EntityRegistrantName> <dei:EntityVoluntaryFilers
contextRef="January-01-2009_June-30-2009">No</dei:EntityVoluntaryFilers> <dei:EntityWellKnownSeasonedIssuer
contextRef="January-01-2009_June-30-2009">No</dei:EntityWellKnownSeasonedIssuer>
<us-gaap:AccountsPayable contextRef="BalanceAsOf_31Dec2008" unitRef="USD"
decimals="-3">107417000</us-gaap:AccountsPayable> <us-gaap:AccountsPayable
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">210941000</us-gaap:AccountsPayable>
<us-gaap:AccountsReceivableNetCurrent contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">446665000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="BalanceAsOf_30Jun2009"
unitRef="USD" decimals="-3">511286000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-3">-11106000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">11293000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AdditionalPaidInCapital contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">6073957000</us-gaap:AdditionalPaidInCapital> <us-gaap:AdditionalPaidInCapital
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">6142936000</us-gaap:AdditionalPaidInCapital>
<us-gaap:AmortizationOfIntangibleAssets
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">147650000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">72869000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">182482000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">93234000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:Assets contextRef="BalanceAsOf_31Dec2008" unitRef="USD"
decimals="-3">8478991000</us-gaap:Assets> <us-gaap:Assets
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">8777196000</us-gaap:Assets>
<us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2008" unitRef="USD"
decimals="-3">2458000000</us-gaap:AssetsCurrent> <us-gaap:AssetsCurrent
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">2744278000</us-gaap:AssetsCurrent>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="BalanceAsOf_31Dec2007" unitRef="USD" decimals="-3">659662000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="BalanceAsOf_30Jun2008" unitRef="USD" decimals="-3">466493000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-3">622385000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">786804000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-195300000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">162304000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CommitmentsAndContingencies xsi:nil="true"
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" /> <us-gaap:CommitmentsAndContingencies
xsi:nil="true" contextRef="BalanceAsOf_30Jun2009" unitRef="USD" /> <us-gaap:CommonStockParOrStatedValuePerShare
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="4">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="4">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">149000</us-gaap:CommonStockValue> <us-gaap:CommonStockValue
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">149000</us-gaap:CommonStockValue>
<us-gaap:CostOfRevenue contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">193335000</us-gaap:CostOfRevenue> <us-gaap:CostOfRevenue
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">92401000</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="January-01-2009_June-30-2009"
unitRef="USD" decimals="-3">188918000</us-gaap:CostOfRevenue> <us-gaap:CostOfRevenue
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">90721000</us-gaap:CostOfRevenue>
<us-gaap:CostsAndExpenses contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">1392829000</us-gaap:CostsAndExpenses> <us-gaap:CostsAndExpenses
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">696647000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="January-01-2009_June-30-2009"
unitRef="USD" decimals="-3">1601902000</us-gaap:CostsAndExpenses> <us-gaap:CostsAndExpenses
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">870375000</us-gaap:CostsAndExpenses>
<us-gaap:DeferredIncomeTaxExpenseBenefit
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-14757000</us-gaap:DeferredIncomeTaxExpenseBenefit>
<us-gaap:DeferredIncomeTaxExpenseBenefit
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-42772000</us-gaap:DeferredIncomeTaxExpenseBenefit>
<us-gaap:DeferredTaxLiabilitiesNoncurrent
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-3">356017000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
<us-gaap:DeferredTaxLiabilitiesNoncurrent
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">310962000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
<us-gaap:DepreciationAndAmortization
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">212471000</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">248877000</us-gaap:DepreciationAndAmortization>
<us-gaap:EarningsPerShareBasic contextRef="SixMonthsEnded_30Jun2008"
unitRef="USDEPS" decimals="2">1.26</us-gaap:EarningsPerShareBasic> <us-gaap:EarningsPerShareBasic
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USDEPS" decimals="2">0.71</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="January-01-2009_June-30-2009"
unitRef="USDEPS" decimals="2">1.34</us-gaap:EarningsPerShareBasic> <us-gaap:EarningsPerShareBasic
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USDEPS" decimals="2">0.49</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="SixMonthsEnded_30Jun2008"
unitRef="USDEPS" decimals="2">1.24</us-gaap:EarningsPerShareDiluted> <us-gaap:EarningsPerShareDiluted
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USDEPS" decimals="2">0.7</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted
contextRef="January-01-2009_June-30-2009" unitRef="USDEPS" decimals="2">1.33</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="ThreeMonthsEnded_30Jun2009"
unitRef="USDEPS" decimals="2">0.49</us-gaap:EarningsPerShareDiluted> <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">2131000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">2115000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">18448000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">2800000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
<us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-18448000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
<us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-2800000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
<us-gaap:GainLossOnInvestments contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">-5928000</us-gaap:GainLossOnInvestments> <us-gaap:GainLossOnInvestments
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-15434000</us-gaap:GainLossOnInvestments>
<us-gaap:Goodwill contextRef="BalanceAsOf_31Dec2008" unitRef="USD"
decimals="-3">1138621000</us-gaap:Goodwill> <us-gaap:Goodwill
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">1138621000</us-gaap:Goodwill>
<us-gaap:ImpairmentOfInvestments contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">15451000</us-gaap:ImpairmentOfInvestments> <us-gaap:ImpairmentOfInvestments
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">10002000</us-gaap:ImpairmentOfInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">541863000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">292779000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">549398000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">237594000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeTaxExpenseBenefit contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">167983000</us-gaap:IncomeTaxExpenseBenefit> <us-gaap:IncomeTaxExpenseBenefit
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">84706000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">157934000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="ThreeMonthsEnded_30Jun2009"
unitRef="USD" decimals="-3">92709000</us-gaap:IncomeTaxExpenseBenefit> <us-gaap:IncreaseDecreaseInAccountsReceivable
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-86302000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-63842000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">101412000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">22950000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInInventories
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-28187000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-14353000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInOtherOperatingAssets
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-7427000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
<us-gaap:IncreaseDecreaseInOtherOperatingAssets
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-5537000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">3741000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-90748000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
<us-gaap:IntangibleAssetsNetExcludingGoodwill
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-3">2161058000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">1978519000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:InventoryNet contextRef="BalanceAsOf_31Dec2008" unitRef="USD"
decimals="-3">263602000</us-gaap:InventoryNet> <us-gaap:InventoryNet
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">268529000</us-gaap:InventoryNet>
<us-gaap:Liabilities contextRef="BalanceAsOf_31Dec2008" unitRef="USD"
decimals="-3">2645039000</us-gaap:Liabilities> <us-gaap:Liabilities
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">2531491000</us-gaap:Liabilities>
<us-gaap:LiabilitiesAndStockholdersEquity
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-3">8478991000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">8777196000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">923222000</us-gaap:LiabilitiesCurrent> <us-gaap:LiabilitiesCurrent
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">803926000</us-gaap:LiabilitiesCurrent>
<us-gaap:LongTermNotesPayable contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">1085431000</us-gaap:LongTermNotesPayable> <us-gaap:LongTermNotesPayable
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">1085607000</us-gaap:LongTermNotesPayable>
<us-gaap:MarketableSecuritiesCurrent contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">719586000</us-gaap:MarketableSecuritiesCurrent>
<us-gaap:MarketableSecuritiesCurrent contextRef="BalanceAsOf_30Jun2009"
unitRef="USD" decimals="-3">836270000</us-gaap:MarketableSecuritiesCurrent>
<us-gaap:MarketableSecuritiesNoncurrent
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-3">891406000</us-gaap:MarketableSecuritiesNoncurrent>
<us-gaap:MarketableSecuritiesNoncurrent
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">1047611000</us-gaap:MarketableSecuritiesNoncurrent>
<us-gaap:NetCashProvidedByUsedInFinancingActivities
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-1037661000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-63777000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">199354000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-303220000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">643007000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">529301000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetIncomeLoss contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">369725000</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">206628000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="January-01-2009_June-30-2009"
unitRef="USD" decimals="-3">386832000</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">142845000</us-gaap:NetIncomeLoss>
<us-gaap:NotesPayableCurrent contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">27667000</us-gaap:NotesPayableCurrent> <us-gaap:NotesPayableCurrent
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">14697000</us-gaap:NotesPayableCurrent>
<us-gaap:OperatingIncomeLoss contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">542801000</us-gaap:OperatingIncomeLoss> <us-gaap:OperatingIncomeLoss
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">296797000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="January-01-2009_June-30-2009"
unitRef="USD" decimals="-3">527872000</us-gaap:OperatingIncomeLoss> <us-gaap:OperatingIncomeLoss
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">222914000</us-gaap:OperatingIncomeLoss>
<us-gaap:OtherAssetsCurrent contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">139400000</us-gaap:OtherAssetsCurrent> <us-gaap:OtherAssetsCurrent
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">143183000</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">235152000</us-gaap:OtherAssetsNoncurrent> <us-gaap:OtherAssetsNoncurrent
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">259507000</us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">534887000</us-gaap:OtherLiabilitiesCurrent> <us-gaap:OtherLiabilitiesCurrent
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">496694000</us-gaap:OtherLiabilitiesCurrent>
<us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">280369000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_30Jun2009"
unitRef="USD" decimals="-3">330996000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:OtherNoncashExpense contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">12151000</us-gaap:OtherNoncashExpense> <us-gaap:OtherNoncashExpense
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-7592000</us-gaap:OtherNoncashExpense>
<us-gaap:OtherNonoperatingIncomeExpense
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-938000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-4018000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">21526000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">14680000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherSalesRevenueNet contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">60029000</us-gaap:OtherSalesRevenueNet> <us-gaap:OtherSalesRevenueNet
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">30136000</us-gaap:OtherSalesRevenueNet>
<us-gaap:OtherSalesRevenueNet contextRef="January-01-2009_June-30-2009"
unitRef="USD" decimals="-3">51008000</us-gaap:OtherSalesRevenueNet> <us-gaap:OtherSalesRevenueNet
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">26749000</us-gaap:OtherSalesRevenueNet>
<us-gaap:PaymentsForRepurchaseOfCommonStock
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-559767000</us-gaap:PaymentsForRepurchaseOfCommonStock>
<us-gaap:PaymentsForRepurchaseOfCommonStock
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-57631000</us-gaap:PaymentsForRepurchaseOfCommonStock>
<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-25000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
<us-gaap:PaymentsToAcquireMarketableSecurities
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-1060159000</us-gaap:PaymentsToAcquireMarketableSecurities>
<us-gaap:PaymentsToAcquireMarketableSecurities
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-1869415000</us-gaap:PaymentsToAcquireMarketableSecurities>
<us-gaap:PaymentsToAcquireOtherInvestments
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-11611000</us-gaap:PaymentsToAcquireOtherInvestments>
<us-gaap:PaymentsToAcquireOtherInvestments
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-35202000</us-gaap:PaymentsToAcquireOtherInvestments>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">-157093000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-71721000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PreferredStockParOrStatedValuePerShare
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockValue contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue> <us-gaap:PreferredStockValue
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">89532000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">24387000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
<us-gaap:ProceedsFromRepaymentsOfBankOverdrafts
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">873000</us-gaap:ProceedsFromRepaymentsOfBankOverdrafts>
<us-gaap:ProceedsFromRepaymentsOfBankOverdrafts
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">7525000</us-gaap:ProceedsFromRepaymentsOfBankOverdrafts>
<us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">1391949000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
<us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">1637562000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
<us-gaap:ProceedsFromShortTermDebt contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">986980000</us-gaap:ProceedsFromShortTermDebt>
<us-gaap:ProceedsFromShortTermDebt
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromShortTermDebt>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">1594754000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_30Jun2009"
unitRef="USD" decimals="-3">1608660000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:RepaymentsOfShortTermDebt contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">-1512474000</us-gaap:RepaymentsOfShortTermDebt>
<us-gaap:RepaymentsOfShortTermDebt
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">-10867000</us-gaap:RepaymentsOfShortTermDebt>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">510491000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">252259000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">695931000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">416453000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentInProcess
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">25000000</us-gaap:ResearchAndDevelopmentInProcess>
<us-gaap:ResearchAndDevelopmentInProcess
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>
<us-gaap:ResearchAndDevelopmentInProcess
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>
<us-gaap:ResearchAndDevelopmentInProcess
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>
<us-gaap:RetainedEarningsAccumulatedDeficit
contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-3">270180000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">516632000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:Revenues contextRef="SixMonthsEnded_30Jun2008" unitRef="USD"
decimals="-3">1935630000</us-gaap:Revenues> <us-gaap:Revenues
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">993444000</us-gaap:Revenues>
<us-gaap:Revenues contextRef="January-01-2009_June-30-2009" unitRef="USD"
decimals="-3">2129774000</us-gaap:Revenues> <us-gaap:Revenues
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">1093289000</us-gaap:Revenues>
<us-gaap:SalesRevenueGoodsNet contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">1349556000</us-gaap:SalesRevenueGoodsNet> <us-gaap:SalesRevenueGoodsNet
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">684486000</us-gaap:SalesRevenueGoodsNet>
<us-gaap:SalesRevenueGoodsNet contextRef="January-01-2009_June-30-2009"
unitRef="USD" decimals="-3">1524378000</us-gaap:SalesRevenueGoodsNet> <us-gaap:SalesRevenueGoodsNet
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">790970000</us-gaap:SalesRevenueGoodsNet>
<us-gaap:SellingGeneralAndAdministrativeExpense
contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">461518000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-3">245689000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">442660000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-3">220829000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:ShareBasedCompensation contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">67647000</us-gaap:ShareBasedCompensation> <us-gaap:ShareBasedCompensation
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">78892000</us-gaap:ShareBasedCompensation>
<us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">5833952000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">6245705000</us-gaap:StockholdersEquity>
<us-gaap:TaxesPayable contextRef="BalanceAsOf_31Dec2008" unitRef="USD"
decimals="-3">223260000</us-gaap:TaxesPayable> <us-gaap:TaxesPayable
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">81594000</us-gaap:TaxesPayable>
<us-gaap:TreasuryStockValue contextRef="BalanceAsOf_31Dec2008"
unitRef="USD" decimals="-3">-527097000</us-gaap:TreasuryStockValue> <us-gaap:TreasuryStockValue
contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-3">-458472000</us-gaap:TreasuryStockValue>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="SixMonthsEnded_30Jun2008" unitRef="Shares" decimals="-3">296554000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="Shares" decimals="-3">293476000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="January-01-2009_June-30-2009" unitRef="Shares" decimals="-3">290014000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="Shares" decimals="-3">290359000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="SixMonthsEnded_30Jun2008" unitRef="Shares" decimals="-3">293268000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="ThreeMonthsEnded_30Jun2008" unitRef="Shares" decimals="-3">290356000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="January-01-2009_June-30-2009" unitRef="Shares" decimals="-3">288162000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="ThreeMonthsEnded_30Jun2009" unitRef="Shares" decimals="-3">288615000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WriteOffOfInventory contextRef="SixMonthsEnded_30Jun2008"
unitRef="USD" decimals="-3">9838000</us-gaap:WriteOffOfInventory> <us-gaap:WriteOffOfInventory
contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-3">11475000</us-gaap:WriteOffOfInventory>
<!--Footnote Section--> </xbrl>

